<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Viruses</journal-id><journal-id journal-id-type="iso-abbrev">Viruses</journal-id><journal-id journal-id-type="pmc-domain-id">1559</journal-id><journal-id journal-id-type="pmc-domain">viruses</journal-id><journal-id journal-id-type="publisher-id">viruses</journal-id><journal-title-group><journal-title>Viruses</journal-title></journal-title-group><issn pub-type="epub">1999-4915</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC8622245</article-id><article-id pub-id-type="pmcid-ver">PMC8622245.1</article-id><article-id pub-id-type="pmcaid">8622245</article-id><article-id pub-id-type="pmcaiid">8622245</article-id><article-id pub-id-type="pmid">34835108</article-id><article-id pub-id-type="doi">10.3390/v13112302</article-id><article-id pub-id-type="publisher-id">viruses-13-02302</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>An Overview of Recent Insights into the Response of TLR to SARS-CoV-2 Infection and the Potential of TLR Agonists as SARS-CoV-2 Vaccine Adjuvants</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4806-9843</contrib-id><name name-style="western"><surname>Kayesh</surname><given-names initials="MEH">Mohammad Enamul Hoque</given-names></name><xref rid="af1-viruses-13-02302" ref-type="aff">1</xref><xref rid="af2-viruses-13-02302" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2130-5837</contrib-id><name name-style="western"><surname>Kohara</surname><given-names initials="M">Michinori</given-names></name><xref rid="af3-viruses-13-02302" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4403-2018</contrib-id><name name-style="western"><surname>Tsukiyama-Kohara</surname><given-names initials="K">Kyoko</given-names></name><xref rid="af1-viruses-13-02302" ref-type="aff">1</xref><xref rid="c1-viruses-13-02302" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Freed</surname><given-names initials="EO">Eric O.</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-viruses-13-02302"><label>1</label>Transboundary Animal Diseases Centre, Joint Faculty of Veterinary Medicine, Kagoshima University, Kagoshima 890-0065, Japan; <email>mehkayesh@pstu.ac.bd</email></aff><aff id="af2-viruses-13-02302"><label>2</label>Department of Microbiology and Public Health, Faculty of Animal Science and Veterinary Medicine, Patuakhali Science and Technology University, Barishal 8210, Bangladesh</aff><aff id="af3-viruses-13-02302"><label>3</label>Department of Microbiology and Cell Biology, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan; <email>kohara-mc@igakuken.or.jp</email></aff><author-notes><corresp id="c1-viruses-13-02302"><label>*</label>Correspondence: <email>kkohara@vet.kagoshima-u.ac.jp</email></corresp></author-notes><pub-date pub-type="epub"><day>18</day><month>11</month><year>2021</year></pub-date><pub-date pub-type="collection"><month>11</month><year>2021</year></pub-date><volume>13</volume><issue>11</issue><issue-id pub-id-type="pmc-issue-id">393509</issue-id><elocation-id>2302</elocation-id><history><date date-type="received"><day>11</day><month>10</month><year>2021</year></date><date date-type="accepted"><day>17</day><month>11</month><year>2021</year></date></history><pub-history><event event-type="pmc-release"><date><day>18</day><month>11</month><year>2021</year></date></event><event event-type="pmc-live"><date><day>27</day><month>11</month><year>2021</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-11 00:25:16.570"><day>11</day><month>09</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2021 by the authors.</copyright-statement><copyright-year>2021</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="viruses-13-02302.pdf"/><abstract><p>The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to coronavirus disease (COVID-19), a global health pandemic causing millions of deaths worldwide. However, the immunopathogenesis of COVID-19, particularly the interaction between SARS-CoV-2 and host innate immunity, remains unclear. The innate immune system acts as the first line of host defense, which is critical for the initial detection of invading pathogens and the activation and shaping of adaptive immunity. Toll-like receptors (TLRs) are key sensors of innate immunity that recognize pathogen-associated molecular patterns and activate downstream signaling for pro-inflammatory cytokine and chemokine production. However, TLRs may also act as a double-edged sword, and dysregulated TLR responses may enhance immune-mediated pathology, instead of providing protection. Therefore, a proper understanding of the interaction between TLRs and SARS-CoV-2 is of great importance for devising therapeutic and preventive strategies. The use of TLR agonists as vaccine adjuvants for human disease is a promising approach that could be applied in the investigation of COVID-19 vaccines. In this review, we discuss the recent progress in our understanding of host innate immune responses in SARS-CoV-2 infection, with particular focus on TLR response. In addition, we discuss the use of TLR agonists as vaccine adjuvants in enhancing the efficacy of COVID-19 vaccine.</p></abstract><kwd-group><kwd>SARS-CoV-2</kwd><kwd>TLRs</kwd><kwd>TLR agonist</kwd><kwd>vaccine</kwd><kwd>adjuvants</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-viruses-13-02302"><title>1. Introduction</title><p>Coronaviruses (CoVs) are agents of emerging and re-emerging infection that pose a significant challenge to human health [<xref rid="B1-viruses-13-02302" ref-type="bibr">1</xref>]. CoVs have a wide host range, including a variety of avian and mammalian species [<xref rid="B2-viruses-13-02302" ref-type="bibr">2</xref>,<xref rid="B3-viruses-13-02302" ref-type="bibr">3</xref>]. CoVs are members of the family <italic toggle="yes">Coronaviridae</italic>, which has four genera, including <italic toggle="yes">Alphacoronavirus</italic>, <italic toggle="yes">Betacoronavirus</italic>, <italic toggle="yes">Gammacoronavirus</italic>, and <italic toggle="yes">Deltacoronavirus</italic> [<xref rid="B4-viruses-13-02302" ref-type="bibr">4</xref>]. The first human CoV, B814, was reported in 1965 [<xref rid="B5-viruses-13-02302" ref-type="bibr">5</xref>]. To date, seven human CoVs (HCoVs) have been identified, including two alpha-CoVs (HCoV-229E and HCoV-NL63) and five beta-CoVs (HCoV-OC43, HCoV-HKU1, severe acute respiratory syndrome (SARS)-CoV, Middle East respiratory syndrome (MERS)-CoV, and SARS-CoV-2) [<xref rid="B4-viruses-13-02302" ref-type="bibr">4</xref>]. However, SARS-CoV-2 is one of the most pathogenic and highly infectious zoonotic CoVs. SARS-CoV-2 contains a positive-sense single-stranded RNA genome, with a size of 29.9 kb [<xref rid="B6-viruses-13-02302" ref-type="bibr">6</xref>]. It contains 4 structural proteins, including surface (S), envelope (E), membrane (M), and nucleocapsid (N) [<xref rid="B7-viruses-13-02302" ref-type="bibr">7</xref>]; 16 non-structural proteins (NSP1&#8211;16); and nine accessory proteins [<xref rid="B8-viruses-13-02302" ref-type="bibr">8</xref>]. The ongoing coronavirus disease (COVID-19) pandemic was caused by SARS-CoV-2 [<xref rid="B9-viruses-13-02302" ref-type="bibr">9</xref>], which is the third zoonotic CoV infecting humans in a short span of only two decades, after the emergence of SARS-CoV in 2002 [<xref rid="B10-viruses-13-02302" ref-type="bibr">10</xref>] and MERS-CoV in 2012 [<xref rid="B11-viruses-13-02302" ref-type="bibr">11</xref>]. Since the emergence of SARS-CoV-2 in Wuhan, China in December 2019, it has rapidly spread worldwide, and as of 30 September 2021, there have been 233,136,147 confirmed cases of COVID-19, including 4,771,408 deaths globally [<xref rid="B12-viruses-13-02302" ref-type="bibr">12</xref>]. The COVID-19 epidemic was declared a global pandemic on 11 March 2020 by the World Health Organization and still continues [<xref rid="B13-viruses-13-02302" ref-type="bibr">13</xref>]. The immunopathogenesis of SARS-CoV-2 remains unclear. In addition, several new variants of the virus have also evolved, which may threaten the success of the currently available SARS-CoV-2 vaccines [<xref rid="B14-viruses-13-02302" ref-type="bibr">14</xref>]. Thus, there is a need for further investigation of the host immune response to SARS-CoV-2 infection, including newly emerging variants, as well as the efficacy of vaccines against them.</p><p>The innate immune system is a key component of host immunity and acts as the first line of defense against invading pathogens, including viruses [<xref rid="B15-viruses-13-02302" ref-type="bibr">15</xref>]. The innate immune response is elicited upon detection of conserved structures on microbes, which are known as pathogen-associated molecular patterns (PAMPs) [<xref rid="B16-viruses-13-02302" ref-type="bibr">16</xref>]. The key innate immune sensing receptors are germ line-encoded pattern-recognition receptors (PRRs), which mediate the initial sensing of infection by recognition of PAMPs, upon microbial invasion of the host [<xref rid="B17-viruses-13-02302" ref-type="bibr">17</xref>,<xref rid="B18-viruses-13-02302" ref-type="bibr">18</xref>]. PRRs recognize molecules released by damaged cells, which are known as damage-associated molecular patterns [<xref rid="B19-viruses-13-02302" ref-type="bibr">19</xref>]. PRRs belong to different families, including Toll-like receptors (TLRs), retinoic acid-inducible gene I (RIG)-like receptors, nucleotide-binding oligomerization domain-containing protein-like receptors, C-type lectin receptors, and DNA-sensing receptors [<xref rid="B16-viruses-13-02302" ref-type="bibr">16</xref>,<xref rid="B17-viruses-13-02302" ref-type="bibr">17</xref>]. TLRs are the key components of innate immunity that are evolutionarily conserved and play an important role in early host defense [<xref rid="B15-viruses-13-02302" ref-type="bibr">15</xref>,<xref rid="B17-viruses-13-02302" ref-type="bibr">17</xref>], by recognizing PAMPs of invading microorganisms, initiating innate immune responses, and shaping adaptive immunity [<xref rid="B20-viruses-13-02302" ref-type="bibr">20</xref>,<xref rid="B21-viruses-13-02302" ref-type="bibr">21</xref>,<xref rid="B22-viruses-13-02302" ref-type="bibr">22</xref>]. TLRs are encoded by a large gene family that includes 10 and 12 members in humans (TLR1&#8211;TLR10) and mice (TLR1&#8211;TLR9 and TLR11&#8211;TLR13), respectively [<xref rid="B23-viruses-13-02302" ref-type="bibr">23</xref>]. TLRs can be localized either on the cell surface, such as TLRs 1, 2, 4, 5, 6, and 10, or on the endoplasmic reticulum, such as TLRs 3, 7, 8, and 9 [<xref rid="B24-viruses-13-02302" ref-type="bibr">24</xref>,<xref rid="B25-viruses-13-02302" ref-type="bibr">25</xref>]. TLR response ultimately may lead to the induction of interferons (IFNs), cytokines, and chemokines by several distinct signaling pathways, thereby limiting infection and promoting adaptive immune responses [<xref rid="B17-viruses-13-02302" ref-type="bibr">17</xref>,<xref rid="B26-viruses-13-02302" ref-type="bibr">26</xref>]. However, TLR activation may act as a double-edged sword, and its dysregulated response may lead to immune-mediated pathology, instead of protection [<xref rid="B27-viruses-13-02302" ref-type="bibr">27</xref>,<xref rid="B28-viruses-13-02302" ref-type="bibr">28</xref>,<xref rid="B29-viruses-13-02302" ref-type="bibr">29</xref>], which has also been observed in cases of SARS-CoV-2 infection [<xref rid="B30-viruses-13-02302" ref-type="bibr">30</xref>]. Therefore, a clear understanding of the role of TLRs in SARS-CoV-2 infection is critical for learning about the immunopathogenesis involved and for the development of therapeutic and preventive strategies against the disease. The focus of this article is to provide an overview of our recent understanding of TLR response to SARS-CoV-2 infection. In addition, the potential of TLR agonists as adjuvants for COVID-19 vaccines has also been discussed herein.</p></sec><sec id="sec2-viruses-13-02302"><title>2. TLR Response to SARS-CoV-2 Infection</title><p>The innate immune response is a key issue to act as the first line of defense against many viral infections [<xref rid="B31-viruses-13-02302" ref-type="bibr">31</xref>]. However, the innate immune response does not always work for the host defense but also induces pathogenesis [<xref rid="B32-viruses-13-02302" ref-type="bibr">32</xref>]. TLRs constitute the most important family of PRRs. TLR signaling is involved in the regulation of both pro- and anti-inflammatory cytokines secretion working for early innate immune responses and adaptive immunity [<xref rid="B33-viruses-13-02302" ref-type="bibr">33</xref>]. TLR activation can act as a double-edged sword, which may activate immune-mediated pathogenesis instead of inducing an immune response which works for defense against pathogens [<xref rid="B27-viruses-13-02302" ref-type="bibr">27</xref>,<xref rid="B28-viruses-13-02302" ref-type="bibr">28</xref>,<xref rid="B34-viruses-13-02302" ref-type="bibr">34</xref>].</p><p>The host immune response to SARS-CoV-2 infection is critical in determining the severity of COVID-19 [<xref rid="B35-viruses-13-02302" ref-type="bibr">35</xref>]. It is assumed that cytokine storms, which are the consequence of hyperinflammation driven by innate immunity, play an important role in the pathogenesis of severe COVID-19 [<xref rid="B36-viruses-13-02302" ref-type="bibr">36</xref>]; however, the underlying mechanisms of the altered pathological inflammation in COVID-19 remain largely unknown. Nevertheless, previous studies on related CoVs, including SARS-CoV and MERS-CoV [<xref rid="B37-viruses-13-02302" ref-type="bibr">37</xref>,<xref rid="B38-viruses-13-02302" ref-type="bibr">38</xref>,<xref rid="B39-viruses-13-02302" ref-type="bibr">39</xref>,<xref rid="B40-viruses-13-02302" ref-type="bibr">40</xref>], have enhanced our understanding of SARS-CoV-2 infection. Moreover, in silico studies have also promoted the understanding of SARS-CoV-2 interactions in the host. It has been indicated that cell surface TLRs, mainly TLR4, are most likely to be involved in sensing molecular patterns, including SARS-CoV-2 S protein, to induce inflammatory responses [<xref rid="B41-viruses-13-02302" ref-type="bibr">41</xref>,<xref rid="B42-viruses-13-02302" ref-type="bibr">42</xref>]. It has been reported that the SARS-CoV-2 S protein S1 subunit can induce pro-inflammatory cytokines through TLR4 signaling in murine and human macrophages, and inhibition of TLR4 by using its antagonist attenuates pro-inflammatory cytokine induction [<xref rid="B43-viruses-13-02302" ref-type="bibr">43</xref>], suggesting that TLR4 is a therapeutic target for controlling COVID-19 severity caused by TLR4-mediated hyperinflammation. Another in vitro study also demonstrated the sensing of SARS-CoV-2 S protein by TLR4 and subsequent induction of interleukin (IL)-1B [<xref rid="B44-viruses-13-02302" ref-type="bibr">44</xref>]. It has also been indicated that SARS-CoV-2 S protein can bind to bacterial lipopolysaccharide, a ligand for TLR4 activation [<xref rid="B45-viruses-13-02302" ref-type="bibr">45</xref>]. SARS-CoV-2-mediated TLR4 and TLR7 upregulation upon periodic thermomechanical modulation has been observed in adipose-derived mesenchymal stromal cells [<xref rid="B46-viruses-13-02302" ref-type="bibr">46</xref>]. The expression of interleukin-1 receptor-associated kinase M (IRAK-M), a negative regulator of TLR signaling [<xref rid="B47-viruses-13-02302" ref-type="bibr">47</xref>], is suppressed by SARS-CoV-2 S protein in macrophages [<xref rid="B48-viruses-13-02302" ref-type="bibr">48</xref>], which may promote pro-inflammatory cytokine production.</p><p>It is considered that pro-inflammatory cytokines greatly contribute to the pathogenesis of COVID-19 and its severity. Zheng et al. reported the sensing of SARS-CoV-2 E protein by TLR2, which results in the hyperexpression of pro-inflammatory cytokines (<xref rid="viruses-13-02302-f001" ref-type="fig">Figure 1</xref>) that may contribute to disease severity [<xref rid="B30-viruses-13-02302" ref-type="bibr">30</xref>], suggesting that TLR2-mediated inflammation plays a pathogenic role in SARS-CoV-2 infection. TLR1, TLR4, TLR5, TLR8, and TLR9 expression levels were also significantly elevated in severe and critical COVID-19 patients; however, TLR3 expression was not correlated with the development of COVID-19, and an increased expression of TLR7 was observed only in patients with moderate COVID-19 [<xref rid="B30-viruses-13-02302" ref-type="bibr">30</xref>]. In a preprint study, another group reported TLR2 activation by SARS-CoV-2 S protein, but not the E protein, and subsequent production of cytokines and chemokines (<xref rid="viruses-13-02302-f001" ref-type="fig">Figure 1</xref>) in human and mouse macrophages [<xref rid="B49-viruses-13-02302" ref-type="bibr">49</xref>]. Although this study supports the sensing of SARS-CoV-2 by TLR2, it differs in terms of the sensing protein reported in a previous study [<xref rid="B30-viruses-13-02302" ref-type="bibr">30</xref>], which requires further investigation [<xref rid="B50-viruses-13-02302" ref-type="bibr">50</xref>].</p><p>Another study reported that alveolar macrophages activated by SARS-CoV-2 through TLR signaling may produce IL-1, which further stimulates mast cells to produce IL-6 [<xref rid="B51-viruses-13-02302" ref-type="bibr">51</xref>]. In addition, an association between mast cell/eosinophil activation and COVID-19 inflammation was reported [<xref rid="B52-viruses-13-02302" ref-type="bibr">52</xref>]. A significantly elevated expression of IL-6 and tumor necrosis factor-&#945; (TNF-&#945;) was found to be associated with TLR expression in obese individuals but not in the controls [<xref rid="B53-viruses-13-02302" ref-type="bibr">53</xref>]. TLR/myeloid differentiation factor 88 (MYD88) signaling, which is upregulated in obese individuals, may contribute to the excessive inflammatory response observed in severe infection with SARS-CoV-2 [<xref rid="B54-viruses-13-02302" ref-type="bibr">54</xref>].</p><p>It is also hypothesized that desensitization of TLR7 signaling may occur due to chronic stimulation of TLR7 by intrinsic substrates in obese and elderly people. This may support the virus to replicate more easily, which upon re-sensitization of TLR7 signaling due to severe viral infection could result in an overwhelming TLR7 response that may promote the development of severe COVID-19 [<xref rid="B55-viruses-13-02302" ref-type="bibr">55</xref>]. Several studies have shown that the TLR7 response is critical for favorable outcome of COVID-19 [<xref rid="B56-viruses-13-02302" ref-type="bibr">56</xref>,<xref rid="B57-viruses-13-02302" ref-type="bibr">57</xref>], highlighting the clinical importance of the innate immune system in SARS-CoV-2 infection. However, in an in vitro study, it has been shown that SARS-CoV-2 induces a TLR7/8-dependent type I and III IFN response in peripheral blood mononuclear cells, which could be protective or may contribute to the cytokine storm observed in COVID-19 [<xref rid="B58-viruses-13-02302" ref-type="bibr">58</xref>] and requires future investigation. Although there is a need for further investigation in this regard, IFN-&#945;2b treatment has been shown to reduce viral replication, as well as IL-6 and CRP levels [<xref rid="B59-viruses-13-02302" ref-type="bibr">59</xref>]. There was an upregulation in the levels of TLR4-mediated inflammatory signaling molecules in peripheral blood mononuclear cells from COVID-19 patients (<xref rid="viruses-13-02302-f001" ref-type="fig">Figure 1</xref>), as compared to those in the healthy controls, which may suggest an involvement of TLR4 signaling in the induction of pathological inflammation during COVID-19, suggesting that targeting TLR4-mediated inflammation may serve as a new therapeutic strategy [<xref rid="B60-viruses-13-02302" ref-type="bibr">60</xref>]. Therefore, TLR2 and TLR4 signaling might be involved in the induction of pro-inflammatory mediators. Infrared light therapy has been shown to decrease TLR4-dependent induction of IL-6, IL-8, TNF-&#945;, INF-&#945;, and INF-&#946; in COVID-19 hyperinflammation [<xref rid="B61-viruses-13-02302" ref-type="bibr">61</xref>]. It was observed that a child with hepatitis after SARS-CoV-2 infection had a polymorphism, Gln11Leu (rs179008), in TLR7 [<xref rid="B62-viruses-13-02302" ref-type="bibr">62</xref>], which could impair an efficient initial immune response. Elevated cytokine levels have been linked to SARS-CoV-2 infection in adults (median age, 51 years) [<xref rid="B63-viruses-13-02302" ref-type="bibr">63</xref>]. Another study observed elevated levels of IL-6 and TNF-&#945; in children with COVID-19, as compared to those in controls; however, the increased levels of these cytokines lacked any correlation with disease severity [<xref rid="B64-viruses-13-02302" ref-type="bibr">64</xref>]. It has also been reported that human biological sex, including sex steroids, sex chromosomes, and genomic and epigenetic differences between two sexes, might play a significant role in heterogeneous COVID-19 outcomes by impacting host immune response to SARS-CoV-2 infection [<xref rid="B65-viruses-13-02302" ref-type="bibr">65</xref>]. It has been reported that sensing of viral RNA by TLR7 is sex-biased, where TLR7 escapes X chromosome inactivation, resulting in greater expression in female immune cells [<xref rid="B66-viruses-13-02302" ref-type="bibr">66</xref>]. However, TLR response in SARS-CoV-2 infection based on sex differences largely remains to be investigated. Aging impacts both innate and adaptive arms of the immune system, and TLR expression and function may decline with increased age, which may affect controlling of viral infections [<xref rid="B67-viruses-13-02302" ref-type="bibr">67</xref>,<xref rid="B68-viruses-13-02302" ref-type="bibr">68</xref>]. Aging is linked to high morbidity and mortality in various infections [<xref rid="B69-viruses-13-02302" ref-type="bibr">69</xref>], which is also applicable for SARS-CoV-2 infection [<xref rid="B70-viruses-13-02302" ref-type="bibr">70</xref>,<xref rid="B71-viruses-13-02302" ref-type="bibr">71</xref>]. However, the exact role of aging in TLR response against SARS-CoV-2 infection remains to be investigated. A multi-omics study of immunological responses in COVID-19 patients also revealed increased cytokines and chemokines levels in severe COVID-19 patients [<xref rid="B72-viruses-13-02302" ref-type="bibr">72</xref>], which is also consistent with the findings of a previous study [<xref rid="B73-viruses-13-02302" ref-type="bibr">73</xref>].</p><p>IFN signaling cascade is crucial for controlling viral infection. It has been demonstrated that hypoxia-inducible factor-1&#945; (HIF-1&#945;) is a direct transcriptional suppressor of interferon regulatory factors (IRFs), the transcriptional activators of type-I IFN, and hypoxia suppresses type-I IFN but not NF-&#954;B-dependent pro-inflammatory cytokine production [<xref rid="B74-viruses-13-02302" ref-type="bibr">74</xref>], which may at least partly explain COVID-19 pathogenesis. Increased expression of HIF-1&#945; mRNA has also been reported in myeloid blood cells from critically ill COVID-19 patients, along with the expression of other genes, TLR2 and TLR4 [<xref rid="B75-viruses-13-02302" ref-type="bibr">75</xref>], which could be involved in SARS-CoV-2 sensing. A predominance of cells co-expressing HIF-1&#945; and TLR2 has also been reported [<xref rid="B75-viruses-13-02302" ref-type="bibr">75</xref>]. Another study revealed that peripheral blood immune cells from severe COVID-19 patients have diminished type-I IFN response but enhanced pro-inflammatory IL-6 and TNF-&#945; responses [<xref rid="B76-viruses-13-02302" ref-type="bibr">76</xref>].</p><p>In an in vitro study, it was shown that there was no inhibitory effect of famotidine, a histamine-2 receptor antagonist, on SARS-CoV-2 proteases [<xref rid="B77-viruses-13-02302" ref-type="bibr">77</xref>]; however, although famotidine has been found to reduce the risk of intubation and death in COVID-19 patients [<xref rid="B78-viruses-13-02302" ref-type="bibr">78</xref>,<xref rid="B79-viruses-13-02302" ref-type="bibr">79</xref>], the mechanism involved remains unknown. Recently, it has been reported that famotidine inhibits TLR3-dependent signaling processes that culminate in the activation of IRF3 and the NF-&#954;B pathway in SARS-CoV-2 infection [<xref rid="B80-viruses-13-02302" ref-type="bibr">80</xref>]. In response to SARS-CoV-2 infection in human induced pluripotent stem cell (iPSC)-derived lung organoids, most of the key genes associated with innate immunity, cytokine/chemokines, and inflammasomes, including STAT1/2, IRF7, CCL5, CXCL10, TNF-&#945;, IL-6, IL-8, and IFN were upregulated. In the case of human iPSC-derived neuronal cells, in response to SARS-CoV-2 infection, TLR3, TLR7, OAS2, complement system, and apoptotic genes were found to be activated [<xref rid="B81-viruses-13-02302" ref-type="bibr">81</xref>]. These findings may further enhance our understanding of COVID-19 pathogenesis. Lactoferrin, a naturally occurring non-toxic glycoprotein of the transferrin family, which is synthesized by exocrine glands and neutrophils, has been shown to partially inhibit SARS-CoV-2 replication in Caco-2 intestinal epithelial cells and also induce the expression of TLR3, TLR7, IFNA1, IFNB1, IRF3, IRF7, and MAVS genes [<xref rid="B82-viruses-13-02302" ref-type="bibr">82</xref>], which could be linked to the suppression of viral replication.</p><p>Type I and III IFNs are key antiviral mediators against SARS-CoV-2 infection. An in-depth analysis of the transcriptional response to SARS-CoV-2 revealed suppression of type I and III IFN responses, in addition to induction of chemokine and pro-inflammatory cytokine gene expression [<xref rid="B83-viruses-13-02302" ref-type="bibr">83</xref>]. One preprint study demonstrated the restriction of SARS-CoV-2 spread by a local IFN-I/III response produced by pDCs; in addition, pDCs response was found to be correlated with the severity of the disease, and the response was impaired in severe COVID-19 patients [<xref rid="B84-viruses-13-02302" ref-type="bibr">84</xref>]. Bastard et al. reported that neutralizing auto-antibodies (Abs) against type I IFNs associated with severe COVID-19, of which male patients had the vast majority (95/101, 94%), is suggestive of gender linkage to pathogenic gene encoding auto-Abs [<xref rid="B85-viruses-13-02302" ref-type="bibr">85</xref>]. SARS-CoV-2 also possesses the strategies to escape the innate immune response by encoding a wide range of viral structural and nonstructural protein (nsp), affecting the IFN signaling pathway and impairing the IFN-mediated antiviral responses [<xref rid="B86-viruses-13-02302" ref-type="bibr">86</xref>,<xref rid="B87-viruses-13-02302" ref-type="bibr">87</xref>]. It has been shown that SARS-CoV-2 ORF9b negatively regulates antiviral immunity by suppressing several components of innate immune signaling, including RIG-I, MDA-5, MAVS, TBK1, and IKK&#949;, thereby facilitating viral replication [<xref rid="B88-viruses-13-02302" ref-type="bibr">88</xref>]. It has been reported that SARS-CoV-2 nsp6 and nsp13 inhibit IRF-3 phosphorylation by binding TANK binding kinase 1 (TBK1), resulting in a reduced production of IFN-&#946;, while the ORF6 prevents IRF-3 nuclear translocation by binding importin Karyopherin &#945;2 [<xref rid="B87-viruses-13-02302" ref-type="bibr">87</xref>,<xref rid="B89-viruses-13-02302" ref-type="bibr">89</xref>]. Another study found that SARS-CoV-2 ORF6, ORF8, and nucleocapsid proteins can inhibit type I IFN signaling pathway [<xref rid="B90-viruses-13-02302" ref-type="bibr">90</xref>]. It has been demonstrated that SARS-CoV-2 M protein can suppress the expression of IFN-&#946; expression through ubiquitin-mediated degradation of TBK1 [<xref rid="B91-viruses-13-02302" ref-type="bibr">91</xref>]. For further details on the immune evasion strategies of SARS-CoV-2, please see the recently published review [<xref rid="B92-viruses-13-02302" ref-type="bibr">92</xref>]. However, future investigations are required for clear understanding of the inhibition of TLR signaling by SARS-CoV-2. Therefore, further investigations are required for a clear understanding of the innate immune response, including TLR response, which may open up a new window for therapeutic and preventive strategies against SARS-CoV-2 infection.</p></sec><sec id="sec3-viruses-13-02302"><title>3. TLR Agonists as COVID-19 Vaccine Adjuvants</title><p>There is a growing interest in the use of TLR agonists as immunomodulators for the treatment of inflammation, cancer, infection, allergy, and autoimmunity. The use of TLR agonists to modify immunotherapeutic effects also appears promising [<xref rid="B93-viruses-13-02302" ref-type="bibr">93</xref>,<xref rid="B94-viruses-13-02302" ref-type="bibr">94</xref>,<xref rid="B95-viruses-13-02302" ref-type="bibr">95</xref>,<xref rid="B96-viruses-13-02302" ref-type="bibr">96</xref>,<xref rid="B97-viruses-13-02302" ref-type="bibr">97</xref>,<xref rid="B98-viruses-13-02302" ref-type="bibr">98</xref>,<xref rid="B99-viruses-13-02302" ref-type="bibr">99</xref>]. Moreover, TLRs, which are considered as important triggering molecules of trained immunity, trigger a long-term boosting of innate immune responses [<xref rid="B100-viruses-13-02302" ref-type="bibr">100</xref>]. To combat the COVID-19 pandemic, there is a critical need for the development of efficient and safe vaccines. Vaccine adjuvants are important for enhancing the immune response against corresponding pathogens, and selecting an appropriate adjuvant is important for vaccine efficacy [<xref rid="B101-viruses-13-02302" ref-type="bibr">101</xref>]. It has been reported that second-generation adjuvants that interact with TLRs, such as TLR ligand adjuvants, are superior to first-generation adjuvants, such as Al(OH)<sub>3</sub>. TLR agonist adjuvants may induce dendritic cell maturation, which is lacking in first-generation adjuvants, such as Al(OH)<sub>3</sub> [<xref rid="B102-viruses-13-02302" ref-type="bibr">102</xref>]. TLR agonists are capable of stimulating innate immune responses, which also trigger adaptive immune responses, thereby improving vaccine efficacy.</p><p>Subunit vaccines, for which adjuvants are required to enhance the magnitude and durability of immune responses, are the safest and most widely used vaccine platforms that are suitable against a multitude of infectious diseases. In a study of SARS-CoV-2 subunit vaccines, the combined use of TLR1/2 and TLR3 agonist (L-pampo) was found to be a potent adjuvant; the SARS-CoV-2 antigens, along with L-pampo, induced strong humoral and cellular immune responses, with a substantial decrease in viral load, in a ferret model [<xref rid="B103-viruses-13-02302" ref-type="bibr">103</xref>]. In another study, it was shown that the TLR2/6 agonist INNA-051 significantly reduced viral RNA levels in throat swabs (96% reduction) and nasal wash (93% reduction) [<xref rid="B104-viruses-13-02302" ref-type="bibr">104</xref>], which requires further investigation and may support the clinical development of a therapy based on the prophylactic use of TLR2/6 agonist. The first plant polymer-based TLR4 agonist, inulin acetate, which is synthesized from plant polysaccharide inulin [<xref rid="B105-viruses-13-02302" ref-type="bibr">105</xref>], has been reported to induce strong systemic and mucosal immunity [<xref rid="B106-viruses-13-02302" ref-type="bibr">106</xref>] and may be useful in the development of a COVID-19 vaccine. CpG ODN, Poly I:C, and resiquimod (R848), which are agonists of TLR9, TLR3, and TLR7/8, respectively, were evaluated in candidate vaccines against SARS-CoV [<xref rid="B107-viruses-13-02302" ref-type="bibr">107</xref>], which also supports an investigation into SARS-CoV-2 vaccine.</p><p>In a previous study, CD8+ T cells were found to be augmented to varying degrees by CpG ODN, PolyI:C, and R848 [<xref rid="B107-viruses-13-02302" ref-type="bibr">107</xref>]; it has also been reported that CD8+ T cell responses might play significant role in preventing SARS-CoV-2 infection [<xref rid="B108-viruses-13-02302" ref-type="bibr">108</xref>,<xref rid="B109-viruses-13-02302" ref-type="bibr">109</xref>]. However, alum lacks the ability to stimulate CD4+ and CD8+ T cell responses, which has been shown to coordinate with the antibody responses toward protective immunity against SARS-CoV-2 [<xref rid="B110-viruses-13-02302" ref-type="bibr">110</xref>]. Recently, the efficacy of a COVID-19 subunit vaccine in promoting protective immunity against SARS-CoV-2 was investigated in rhesus macaques [<xref rid="B111-viruses-13-02302" ref-type="bibr">111</xref>]. The vaccine contained the SARS-CoV-2 S protein receptor-binding domain displayed on an I53-50 protein nanoparticle scaffold with five different adjuvants, including a squalene-in-water emulsion (Essai O/W 1849101), an &#945;-tocopherol-containing oil-in-water emulsion (AS03), a TLR7 agonist adsorbed to alum (AS37), a TLR9 agonist formulated in alum (CpG1018-alum), and alum. Notably, variations in the neutralizing antibody production were observed due to the adjuvant differences [<xref rid="B111-viruses-13-02302" ref-type="bibr">111</xref>], which indicates that the selection of an adjuvant is critical for vaccine efficacy. In a phase I, randomized, double-blind, placebo-controlled trial, the SCB-2019 vaccine, comprising of S-trimer protein formulated with either AS03 or CpG/Alum adjuvants, induced strong humoral and cellular immune responses against SARS-CoV-2, with high viral neutralizing activity [<xref rid="B112-viruses-13-02302" ref-type="bibr">112</xref>]. Both the adjuvanted vaccine formulations were well tolerated and supported further clinical development [<xref rid="B112-viruses-13-02302" ref-type="bibr">112</xref>]. It has been suggested that TLR agonists, including imiquimod, an immune stimulator of TLR7, could serve as an effective therapeutic approach in the early stages of COVID-19 [<xref rid="B113-viruses-13-02302" ref-type="bibr">113</xref>] and could be more favorable. However, so far, no phase II and III clinical trial results of TLR agonists for COVID-19 vaccines have been published. The TLR agonists currently under development for COVID-19 vaccines are listed in <xref rid="viruses-13-02302-t001" ref-type="table">Table 1</xref>.</p></sec><sec sec-type="conclusions" id="sec4-viruses-13-02302"><title>4. Conclusions</title><p>Current evidence suggests that the hyperinflammation that results from a dysregulated host innate immune response has a negative effect on the COVID-19 outcome. The innate immune response appears to be a double-edged sword in SARS-CoV-2 infection. Its dysregulated signaling may lead to the production of detrimental pro-inflammatory cytokines and chemokines that cause severe disease, instead of providing protection [<xref rid="B30-viruses-13-02302" ref-type="bibr">30</xref>]. In this review, we discussed the important role of TLRs in shaping the innate response in SARS-CoV-2 infection. From the currently available data, it is assumed that TLRs, mainly TLR2 and TLR4, may play a pathogenic role by inducing hyperinflammation, and thus, may lead to severe COVID-19. The use of TLR antagonists targeting TLR2 and TLR4 might exert a beneficial effect, by attenuating the deleterious hyperinflammatory response triggered by TLR2 and TLR4 upon sensing SARS-CoV-2 S or E protein; thus, this approach warrants further investigation. In addition, a timely optimum TLR response, mainly mediated by TLR3 and TLR7, could play a protective role against SARS-CoV-2 infection. Application of adjuvant with RBD-NP can enhance neutralizing antibody production and CD4 T cell responses through TLRs. It is understood that optimal IFN production and controlled inflammation are necessary for reducing COVID-19 pathogenesis caused by excessive cytokine production, which could be achieved through the regulation of the TLR-mediated response [<xref rid="B114-viruses-13-02302" ref-type="bibr">114</xref>,<xref rid="B115-viruses-13-02302" ref-type="bibr">115</xref>]. Therefore, it is critical to obtain a clear understanding of TLR interactions in SARS-CoV-2 infection, which may provide a new basis for the development of therapeutic and preventive approaches to fight the disease, including a TLR agonist-adjuvanted SARS-CoV-2 vaccine.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s Note:</bold> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, M.E.H.K., M.K. and K.T.-K.; writing&#8212;original draft preparation, M.E.H.K.; writing&#8212;review and editing, M.E.H.K., M.K. and K.T.-K.; supervision, K.T.-K. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Funding</title><p>This study was supported by a grant from the Tokyo Metropolitan Government for the development of a SARS-CoV-2 vaccine and the Japan Agency for Medical Research and Development (AMED).</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-viruses-13-02302"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>V.C.C.</given-names></name><name name-style="western"><surname>Lau</surname><given-names>S.K.P.</given-names></name><name name-style="western"><surname>Woo</surname><given-names>P.C.Y.</given-names></name><name name-style="western"><surname>Yuen</surname><given-names>K.-Y.</given-names></name></person-group><article-title>Severe Acute Respiratory Syndrome Coronavirus as an Agent of Emerging and Reemerging Infection</article-title><source>Clin. Microbiol. Rev.</source><year>2007</year><volume>20</volume><fpage>660</fpage><lpage>694</lpage><pub-id pub-id-type="doi">10.1128/CMR.00023-07</pub-id><pub-id pub-id-type="pmid">17934078</pub-id><pub-id pub-id-type="pmcid">PMC2176051</pub-id></element-citation></ref><ref id="B2-viruses-13-02302"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Su</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>G.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>W.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>A.C.K.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Bi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>G.F.</given-names></name></person-group><article-title>Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses</article-title><source>Trends Microbiol.</source><year>2016</year><volume>24</volume><fpage>490</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2016.03.003</pub-id><pub-id pub-id-type="pmid">27012512</pub-id><pub-id pub-id-type="pmcid">PMC7125511</pub-id></element-citation></ref><ref id="B3-viruses-13-02302"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cavanagh</surname><given-names>D.</given-names></name></person-group><article-title>Coronaviruses in poultry and other birds</article-title><source>Avian Pathol.</source><year>2005</year><volume>34</volume><fpage>439</fpage><lpage>448</lpage><pub-id pub-id-type="doi">10.1080/03079450500367682</pub-id><pub-id pub-id-type="pmid">16537157</pub-id></element-citation></ref><ref id="B4-viruses-13-02302"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cui</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>F.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Z.-L.</given-names></name></person-group><article-title>Origin and evolution of pathogenic coronaviruses</article-title><source>Nat. Rev. Microbiol.</source><year>2019</year><volume>17</volume><fpage>181</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1038/s41579-018-0118-9</pub-id><pub-id pub-id-type="pmid">30531947</pub-id><pub-id pub-id-type="pmcid">PMC7097006</pub-id></element-citation></ref><ref id="B5-viruses-13-02302"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kapikian</surname><given-names>A.Z.</given-names></name></person-group><article-title>The coronaviruses</article-title><source>Dev. Biol. Stand.</source><year>1975</year><volume>28</volume><fpage>42</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">1092577</pub-id></element-citation></ref><ref id="B6-viruses-13-02302"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Niu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Song</surname><given-names>H.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding</article-title><source>Lancet</source><year>2020</year><volume>395</volume><fpage>565</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30251-8</pub-id><pub-id pub-id-type="pmid">32007145</pub-id><pub-id pub-id-type="pmcid">PMC7159086</pub-id></element-citation></ref><ref id="B7-viruses-13-02302"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>D.</given-names></name></person-group><article-title>Emerging coronaviruses: Genome structure, replication, and pathogenesis</article-title><source>J. Med. Virol.</source><year>2020</year><volume>92</volume><fpage>418</fpage><lpage>423</lpage><pub-id pub-id-type="doi">10.1002/jmv.25681</pub-id><pub-id pub-id-type="pmid">31967327</pub-id><pub-id pub-id-type="pmcid">PMC7167049</pub-id></element-citation></ref><ref id="B8-viruses-13-02302"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yadav</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chaudhary</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>N.</given-names></name><name name-style="western"><surname>Chaudhary</surname><given-names>P.</given-names></name><name name-style="western"><surname>Khanra</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dhamija</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Handu</surname><given-names>S.</given-names></name></person-group><article-title>Role of Structural and Non-Structural Proteins and Therapeutic Targets of SARS-CoV-2 for COVID-19</article-title><source>Cells</source><year>2021</year><volume>10</volume><elocation-id>821</elocation-id><pub-id pub-id-type="doi">10.3390/cells10040821</pub-id><pub-id pub-id-type="pmid">33917481</pub-id><pub-id pub-id-type="pmcid">PMC8067447</pub-id></element-citation></ref><ref id="B9-viruses-13-02302"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.-L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.-G.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Si</surname><given-names>H.-R.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C.-L.</given-names></name><etal/></person-group><article-title>A pneumonia outbreak associated with a new coronavirus of probable bat origin</article-title><source>Nature</source><year>2020</year><volume>579</volume><fpage>270</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2012-7</pub-id><pub-id pub-id-type="pmid">32015507</pub-id><pub-id pub-id-type="pmcid">PMC7095418</pub-id></element-citation></ref><ref id="B10-viruses-13-02302"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peiris</surname><given-names>J.S.M.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>V.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hung</surname><given-names>I.F.N.</given-names></name><name name-style="western"><surname>Poon</surname><given-names>L.</given-names></name><name name-style="western"><surname>Law</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hon</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: A prospective study</article-title><source>Lancet</source><year>2003</year><volume>361</volume><fpage>1767</fpage><lpage>1772</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(03)13412-5</pub-id><pub-id pub-id-type="pmid">12781535</pub-id><pub-id pub-id-type="pmcid">PMC7112410</pub-id></element-citation></ref><ref id="B11-viruses-13-02302"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zaki</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Van Boheemen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bestebroer</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Osterhaus</surname><given-names>A.D.M.E.</given-names></name><name name-style="western"><surname>Fouchier</surname><given-names>R.A.M.</given-names></name></person-group><article-title>Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia</article-title><source>N. Engl. J. Med.</source><year>2012</year><volume>367</volume><fpage>1814</fpage><lpage>1820</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1211721</pub-id><pub-id pub-id-type="pmid">23075143</pub-id></element-citation></ref><ref id="B12-viruses-13-02302"><label>12.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>World Health Organization (WHO)</collab></person-group><article-title>WHO Coronavirus (COVID-19) Dashboard</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://covid19.who.int/" ext-link-type="uri">https://covid19.who.int/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-10-01">(accessed on 1 October 2021)</date-in-citation></element-citation></ref><ref id="B13-viruses-13-02302"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cucinotta</surname><given-names>D.</given-names></name><name name-style="western"><surname>Vanelli</surname><given-names>M.</given-names></name></person-group><article-title>WHO declares COVID-19 a pandemic</article-title><source>Acta Biomed.</source><year>2020</year><volume>91</volume><fpage>157</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.23750/abm.v91i1.9397</pub-id><pub-id pub-id-type="pmid">32191675</pub-id><pub-id pub-id-type="pmcid">PMC7569573</pub-id></element-citation></ref><ref id="B14-viruses-13-02302"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harvey</surname><given-names>W.T.</given-names></name><name name-style="western"><surname>Carabelli</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Thomson</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Ludden</surname><given-names>C.</given-names></name><name name-style="western"><surname>Reeve</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rambaut</surname><given-names>A.</given-names></name><name name-style="western"><surname>Peacock</surname><given-names>S.J.</given-names></name><etal/></person-group><article-title>SARS-CoV-2 variants, spike mutations and immune escape</article-title><source>Nat. Rev. Genet.</source><year>2021</year><volume>19</volume><fpage>409</fpage><lpage>424</lpage><pub-id pub-id-type="doi">10.1038/s41579-021-00573-0</pub-id><pub-id pub-id-type="pmid">34075212</pub-id><pub-id pub-id-type="pmcid">PMC8167834</pub-id></element-citation></ref><ref id="B15-viruses-13-02302"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Medzhitov</surname><given-names>R.</given-names></name><name name-style="western"><surname>Janeway</surname><given-names>C.</given-names></name></person-group><article-title>Innate Immunity</article-title><source>N. Engl. J. Med.</source><year>2000</year><volume>343</volume><fpage>338</fpage><lpage>344</lpage><pub-id pub-id-type="doi">10.1056/NEJM200008033430506</pub-id><pub-id pub-id-type="pmid">10922424</pub-id></element-citation></ref><ref id="B16-viruses-13-02302"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mogensen</surname><given-names>T.H.</given-names></name></person-group><article-title>Pathogen Recognition and Inflammatory Signaling in Innate Immune Defenses</article-title><source>Clin. Microbiol. Rev.</source><year>2009</year><volume>22</volume><fpage>240</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1128/CMR.00046-08</pub-id><pub-id pub-id-type="pmid">19366914</pub-id><pub-id pub-id-type="pmcid">PMC2668232</pub-id></element-citation></ref><ref id="B17-viruses-13-02302"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takeuchi</surname><given-names>O.</given-names></name><name name-style="western"><surname>Akira</surname><given-names>S.</given-names></name></person-group><article-title>Pattern Recognition Receptors and Inflammation</article-title><source>Cell</source><year>2010</year><volume>140</volume><fpage>805</fpage><lpage>820</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2010.01.022</pub-id><pub-id pub-id-type="pmid">20303872</pub-id></element-citation></ref><ref id="B18-viruses-13-02302"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akira</surname><given-names>S.</given-names></name><name name-style="western"><surname>Uematsu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Takeuchi</surname><given-names>O.</given-names></name></person-group><article-title>Pathogen recognition and innate immunity</article-title><source>Cell</source><year>2006</year><volume>124</volume><fpage>783</fpage><lpage>801</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2006.02.015</pub-id><pub-id pub-id-type="pmid">16497588</pub-id></element-citation></ref><ref id="B19-viruses-13-02302"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amarante-Mendes</surname><given-names>G.P.</given-names></name><name name-style="western"><surname>Adjemian</surname><given-names>S.</given-names></name><name name-style="western"><surname>Branco</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Zanetti</surname><given-names>L.</given-names></name><name name-style="western"><surname>Weinlich</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bortoluci</surname><given-names>K.R.</given-names></name></person-group><article-title>Pattern Recognition Receptors and the Host Cell Death Molecular Machinery</article-title><source>Front. Immunol.</source><year>2018</year><volume>9</volume><fpage>2379</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.02379</pub-id><pub-id pub-id-type="pmid">30459758</pub-id><pub-id pub-id-type="pmcid">PMC6232773</pub-id></element-citation></ref><ref id="B20-viruses-13-02302"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akira</surname><given-names>S.</given-names></name><name name-style="western"><surname>Takeda</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kaisho</surname><given-names>T.</given-names></name></person-group><article-title>Toll-like receptors: Critical proteins linking innate and acquired immunity</article-title><source>Nat. Immunol.</source><year>2001</year><volume>2</volume><fpage>675</fpage><lpage>680</lpage><pub-id pub-id-type="doi">10.1038/90609</pub-id><pub-id pub-id-type="pmid">11477402</pub-id></element-citation></ref><ref id="B21-viruses-13-02302"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iwasaki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Medzhitov</surname><given-names>R.</given-names></name></person-group><article-title>Toll-like receptor control of the adaptive immune responses</article-title><source>Nat. Immunol.</source><year>2004</year><volume>5</volume><fpage>987</fpage><lpage>995</lpage><pub-id pub-id-type="doi">10.1038/ni1112</pub-id><pub-id pub-id-type="pmid">15454922</pub-id></element-citation></ref><ref id="B22-viruses-13-02302"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takeda</surname><given-names>K.</given-names></name><name name-style="western"><surname>Akira</surname><given-names>S.</given-names></name></person-group><article-title>Toll-like receptors in innate immunity</article-title><source>Int. Immunol.</source><year>2005</year><volume>17</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1093/intimm/dxh186</pub-id><pub-id pub-id-type="pmid">15585605</pub-id></element-citation></ref><ref id="B23-viruses-13-02302"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kawasaki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kawai</surname><given-names>T.</given-names></name></person-group><article-title>Toll-Like Receptor Signaling Pathways</article-title><source>Front. Immunol.</source><year>2014</year><volume>5</volume><fpage>461</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2014.00461</pub-id><pub-id pub-id-type="pmid">25309543</pub-id><pub-id pub-id-type="pmcid">PMC4174766</pub-id></element-citation></ref><ref id="B24-viruses-13-02302"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Neill</surname><given-names>L.A.J.</given-names></name><name name-style="western"><surname>Golenbock</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Bowie</surname><given-names>A.</given-names></name></person-group><article-title>The history of Toll-like receptors&#8212;Redefining innate immunity</article-title><source>Nat. Rev. Immunol.</source><year>2013</year><volume>13</volume><fpage>453</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.1038/nri3446</pub-id><pub-id pub-id-type="pmid">23681101</pub-id></element-citation></ref><ref id="B25-viruses-13-02302"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chaturvedi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pierce</surname><given-names>S.K.</given-names></name></person-group><article-title>How Location Governs Toll-Like Receptor Signaling</article-title><source>Traffic</source><year>2009</year><volume>10</volume><fpage>621</fpage><lpage>628</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0854.2009.00899.x</pub-id><pub-id pub-id-type="pmid">19302269</pub-id><pub-id pub-id-type="pmcid">PMC2741634</pub-id></element-citation></ref><ref id="B26-viruses-13-02302"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kawai</surname><given-names>T.</given-names></name><name name-style="western"><surname>Akira</surname><given-names>S.</given-names></name></person-group><article-title>Toll-like Receptors and Their Crosstalk with Other Innate Receptors in Infection and Immunity</article-title><source>Immunity</source><year>2011</year><volume>34</volume><fpage>637</fpage><lpage>650</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2011.05.006</pub-id><pub-id pub-id-type="pmid">21616434</pub-id></element-citation></ref><ref id="B27-viruses-13-02302"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yokota</surname><given-names>S.-I.</given-names></name><name name-style="western"><surname>Okabayashi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Fujii</surname><given-names>N.</given-names></name></person-group><article-title>The Battle between Virus and Host: Modulation of Toll-Like Receptor Signaling Pathways by Virus Infection</article-title><source>Mediat. Inflamm.</source><year>2010</year><volume>2010</volume><fpage>184328</fpage><pub-id pub-id-type="doi">10.1155/2010/184328</pub-id><pub-id pub-id-type="pmcid">PMC2903949</pub-id><pub-id pub-id-type="pmid">20672047</pub-id></element-citation></ref><ref id="B28-viruses-13-02302"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Unkeless</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Z.H.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>H.</given-names></name></person-group><article-title>TLR signaling by tumor and immune cells: A double-edged sword</article-title><source>Oncogene</source><year>2008</year><volume>27</volume><fpage>218</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1210904</pub-id><pub-id pub-id-type="pmid">18176603</pub-id></element-citation></ref><ref id="B29-viruses-13-02302"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ebermeyer</surname><given-names>T.</given-names></name><name name-style="western"><surname>Cognasse</surname><given-names>F.</given-names></name><name name-style="western"><surname>Berthelot</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mismetti</surname><given-names>P.</given-names></name><name name-style="western"><surname>Garraud</surname><given-names>O.</given-names></name><name name-style="western"><surname>Hamzeh-Cognasse</surname><given-names>H.</given-names></name></person-group><article-title>Platelet Innate Immune Receptors and TLRs: A Double-Edged Sword</article-title><source>Int. J. Mol. Sci.</source><year>2021</year><volume>22</volume><elocation-id>7894</elocation-id><pub-id pub-id-type="doi">10.3390/ijms22157894</pub-id><pub-id pub-id-type="pmid">34360659</pub-id><pub-id pub-id-type="pmcid">PMC8347377</pub-id></element-citation></ref><ref id="B30-viruses-13-02302"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>M.</given-names></name><name name-style="western"><surname>Karki</surname><given-names>R.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>E.P.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fitzpatrick</surname><given-names>E.</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>P.</given-names></name><name name-style="western"><surname>Jonsson</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Kanneganti</surname><given-names>T.-D.</given-names></name></person-group><article-title>TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines</article-title><source>Nat. Immunol.</source><year>2021</year><volume>22</volume><fpage>829</fpage><lpage>838</lpage><pub-id pub-id-type="doi">10.1038/s41590-021-00937-x</pub-id><pub-id pub-id-type="pmid">33963333</pub-id><pub-id pub-id-type="pmcid">PMC8882317</pub-id></element-citation></ref><ref id="B31-viruses-13-02302"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zuniga</surname><given-names>E.I.</given-names></name><name name-style="western"><surname>Macal</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Harker</surname><given-names>J.A.</given-names></name></person-group><article-title>Innate and Adaptive Immune Regulation during Chronic Viral Infections</article-title><source>Annu. Rev. Virol.</source><year>2015</year><volume>2</volume><fpage>573</fpage><lpage>597</lpage><pub-id pub-id-type="doi">10.1146/annurev-virology-100114-055226</pub-id><pub-id pub-id-type="pmid">26958929</pub-id><pub-id pub-id-type="pmcid">PMC4785831</pub-id></element-citation></ref><ref id="B32-viruses-13-02302"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Modhiran</surname><given-names>N.</given-names></name><name name-style="western"><surname>Watterson</surname><given-names>D.</given-names></name><name name-style="western"><surname>Muller</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Panetta</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Sester</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hume</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Stacey</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Young</surname><given-names>P.R.</given-names></name></person-group><article-title>Dengue virus NS1 protein activates cells via Toll-like receptor 4 and disrupts endothelial cell monolayer integrity</article-title><source>Sci. Transl. Med.</source><year>2015</year><volume>7</volume><fpage>304ra142</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.aaa3863</pub-id><pub-id pub-id-type="pmid">26355031</pub-id></element-citation></ref><ref id="B33-viruses-13-02302"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ozato</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tsujimura</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tamura</surname><given-names>T.</given-names></name></person-group><article-title>Toll-Like Receptor Signaling and Regulation of Cytokine Gene Expression in the Immune System</article-title><source>Biotechniques</source><year>2002</year><volume>33</volume><fpage>S66</fpage><lpage>S75</lpage><pub-id pub-id-type="doi">10.2144/Oct0208</pub-id><pub-id pub-id-type="pmid">12395929</pub-id></element-citation></ref><ref id="B34-viruses-13-02302"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salaun</surname><given-names>B.</given-names></name><name name-style="western"><surname>Romero</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lebecque</surname><given-names>S.</given-names></name></person-group><article-title>Toll-like receptors&#8217; two-edged sword: When immunity meets apoptosis</article-title><source>Eur. J. Immunol.</source><year>2007</year><volume>37</volume><fpage>3311</fpage><lpage>3318</lpage><pub-id pub-id-type="doi">10.1002/eji.200737744</pub-id><pub-id pub-id-type="pmid">18034428</pub-id></element-citation></ref><ref id="B35-viruses-13-02302"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>H.R.</given-names></name></person-group><article-title>Role of Host Immune and Inflammatory Responses in COVID-19 Cases with Underlying Primary Immunodeficiency: A Review</article-title><source>J. Interf. Cytokine Res.</source><year>2020</year><volume>40</volume><fpage>549</fpage><lpage>554</lpage><pub-id pub-id-type="doi">10.1089/jir.2020.0210</pub-id><pub-id pub-id-type="pmid">33337932</pub-id><pub-id pub-id-type="pmcid">PMC7757688</pub-id></element-citation></ref><ref id="B36-viruses-13-02302"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ye</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>J.</given-names></name></person-group><article-title>The pathogenesis and treatment of the &#8216;Cytokine Storm&#8217; in COVID-19</article-title><source>J. Infect.</source><year>2020</year><volume>80</volume><fpage>607</fpage><lpage>613</lpage><pub-id pub-id-type="doi">10.1016/j.jinf.2020.03.037</pub-id><pub-id pub-id-type="pmid">32283152</pub-id><pub-id pub-id-type="pmcid">PMC7194613</pub-id></element-citation></ref><ref id="B37-viruses-13-02302"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sheahan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Morrison</surname><given-names>T.E.</given-names></name><name name-style="western"><surname>Funkhouser</surname><given-names>W.</given-names></name><name name-style="western"><surname>Uematsu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Akira</surname><given-names>S.</given-names></name><name name-style="western"><surname>Baric</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Heise</surname><given-names>M.T.</given-names></name></person-group><article-title>MyD88 Is Required for Protection from Lethal Infection with a Mouse-Adapted SARS-CoV</article-title><source>PLoS Pathog.</source><year>2008</year><volume>4</volume><elocation-id>e1000240</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1000240</pub-id><pub-id pub-id-type="pmid">19079579</pub-id><pub-id pub-id-type="pmcid">PMC2587915</pub-id></element-citation></ref><ref id="B38-viruses-13-02302"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Totura</surname><given-names>A.</given-names></name><name name-style="western"><surname>Whitmore</surname><given-names>A.</given-names></name><name name-style="western"><surname>Agnihothram</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sch&#228;fer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Katze</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Heise</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Baric</surname><given-names>R.S.</given-names></name></person-group><article-title>Toll-Like Receptor 3 Signaling via TRIF Contributes to a Protective Innate Immune Response to Severe Acute Respiratory Syndrome Coronavirus Infection</article-title><source>MBio</source><year>2015</year><volume>6</volume><fpage>e00638-15</fpage><pub-id pub-id-type="doi">10.1128/mBio.00638-15</pub-id><pub-id pub-id-type="pmid">26015500</pub-id><pub-id pub-id-type="pmcid">PMC4447251</pub-id></element-citation></ref><ref id="B39-viruses-13-02302"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name></person-group><article-title>The Membrane Protein of Severe Acute Respiratory Syndrome Coronavirus Functions as a Novel Cytosolic Pathogen-Associated Molecular Pattern to Promote Beta Interferon Induction via a Toll-Like-Receptor-Related TRAF3-Independent Mechanism</article-title><source>MBio</source><year>2016</year><volume>7</volume><fpage>e01872-15</fpage><pub-id pub-id-type="doi">10.1128/mBio.01872-15</pub-id><pub-id pub-id-type="pmid">26861016</pub-id><pub-id pub-id-type="pmcid">PMC4752600</pub-id></element-citation></ref><ref id="B40-viruses-13-02302"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spiegel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Weber</surname><given-names>F.</given-names></name></person-group><article-title>Inhibition of cytokine gene expression and induction of chemokine genes in non-lymphatic cells infected with SARS coronavirus</article-title><source>Virol. J.</source><year>2006</year><volume>3</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1186/1743-422X-3-17</pub-id><pub-id pub-id-type="pmid">16571117</pub-id><pub-id pub-id-type="pmcid">PMC1444920</pub-id></element-citation></ref><ref id="B41-viruses-13-02302"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhattacharya</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Mallick</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.-S.</given-names></name><name name-style="western"><surname>Chakraborty</surname><given-names>C.</given-names></name></person-group><article-title>Immunoinformatics approach to understand molecular interaction between multi-epitopic regions of SARS-CoV-2 spike-protein with TLR4/MD-2 complex</article-title><source>Infect. Genet. Evol.</source><year>2020</year><volume>85</volume><fpage>104587</fpage><pub-id pub-id-type="doi">10.1016/j.meegid.2020.104587</pub-id><pub-id pub-id-type="pmid">33039603</pub-id><pub-id pub-id-type="pmcid">PMC7543713</pub-id></element-citation></ref><ref id="B42-viruses-13-02302"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choudhury</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mukherjee</surname><given-names>S.</given-names></name></person-group><article-title>In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs</article-title><source>J. Med. Virol.</source><year>2020</year><volume>92</volume><fpage>2105</fpage><lpage>2113</lpage><pub-id pub-id-type="doi">10.1002/jmv.25987</pub-id><pub-id pub-id-type="pmid">32383269</pub-id><pub-id pub-id-type="pmcid">PMC7267663</pub-id></element-citation></ref><ref id="B43-viruses-13-02302"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shirato</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kizaki</surname><given-names>T.</given-names></name></person-group><article-title>SARS-CoV-2 spike protein S1 subunit induces pro-inflammatory responses via toll-like receptor 4 signaling in murine and human macrophages</article-title><source>Heliyon</source><year>2021</year><volume>7</volume><fpage>e06187</fpage><pub-id pub-id-type="doi">10.1016/j.heliyon.2021.e06187</pub-id><pub-id pub-id-type="pmid">33644468</pub-id><pub-id pub-id-type="pmcid">PMC7887388</pub-id></element-citation></ref><ref id="B44-viruses-13-02302"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kuang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>X.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><etal/></person-group><article-title>SARS-CoV-2 spike protein interacts with and activates TLR41</article-title><source>Cell Res.</source><year>2021</year><volume>31</volume><fpage>1</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1038/s41422-021-00495-9</pub-id><pub-id pub-id-type="pmid">33742149</pub-id><pub-id pub-id-type="pmcid">PMC7975240</pub-id></element-citation></ref><ref id="B45-viruses-13-02302"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petruk</surname><given-names>G.</given-names></name><name name-style="western"><surname>Puthia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Petrlova</surname><given-names>J.</given-names></name><name name-style="western"><surname>Samsudin</surname><given-names>F.</given-names></name><name name-style="western"><surname>Str&#246;mdahl</surname><given-names>A.-C.</given-names></name><name name-style="western"><surname>Cerps</surname><given-names>S.</given-names></name><name name-style="western"><surname>Uller</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kjellstr&#246;m</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bond</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Schmidtchen</surname><given-names>A.A.</given-names></name></person-group><article-title>SARS-CoV-2 spike protein binds to bacterial lipopolysaccharide and boosts proinflammatory activity</article-title><source>J. Mol. Cell Biol.</source><year>2021</year><volume>12</volume><fpage>916</fpage><lpage>932</lpage><pub-id pub-id-type="doi">10.1093/jmcb/mjaa067</pub-id><pub-id pub-id-type="pmid">33295606</pub-id><pub-id pub-id-type="pmcid">PMC7799037</pub-id></element-citation></ref><ref id="B46-viruses-13-02302"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Nie</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lendlein</surname><given-names>A.</given-names></name></person-group><article-title>Periodic thermomechanical modulation of toll-like receptor expression and distribution in mesenchymal stromal cells</article-title><source>MRS Commun.</source><year>2021</year><volume>11</volume><fpage>425</fpage><lpage>431</lpage><pub-id pub-id-type="doi">10.1557/s43579-021-00049-5</pub-id><pub-id pub-id-type="pmcid">PMC8265727</pub-id><pub-id pub-id-type="pmid">34258101</pub-id></element-citation></ref><ref id="B47-viruses-13-02302"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kobayashi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hernandez</surname><given-names>L.D.</given-names></name><name name-style="western"><surname>Gal&#225;n</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Janeway</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Medzhitov</surname><given-names>R.</given-names></name><name name-style="western"><surname>Flavell</surname><given-names>R.A.</given-names></name></person-group><article-title>IRAK-M Is a Negative Regulator of Toll-like Receptor Signaling</article-title><source>Cell</source><year>2002</year><volume>110</volume><fpage>191</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(02)00827-9</pub-id><pub-id pub-id-type="pmid">12150927</pub-id></element-citation></ref><ref id="B48-viruses-13-02302"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pantazi</surname><given-names>I.</given-names></name><name name-style="western"><surname>Al-Qahtani</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Alhamlan</surname><given-names>F.S.</given-names></name><name name-style="western"><surname>Alothaid</surname><given-names>H.</given-names></name><name name-style="western"><surname>Matou-Nasri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sourvinos</surname><given-names>G.</given-names></name><name name-style="western"><surname>Vergadi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tsatsanis</surname><given-names>C.</given-names></name></person-group><article-title>SARS-CoV-2/ACE2 Interaction Suppresses IRAK-M Expression and Promotes Pro-Inflammatory Cytokine Production in Macrophages</article-title><source>Front. Immunol.</source><year>2021</year><volume>12</volume><fpage>683800</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2021.683800</pub-id><pub-id pub-id-type="pmid">34248968</pub-id><pub-id pub-id-type="pmcid">PMC8261299</pub-id></element-citation></ref><ref id="B49-viruses-13-02302"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shafiei</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Longoria</surname><given-names>C.</given-names></name><name name-style="western"><surname>Schoggins</surname><given-names>J.</given-names></name><name name-style="western"><surname>Savani</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Zaki</surname><given-names>H.</given-names></name></person-group><article-title>SARS-CoV-2 spike protein induces inflammation via TLR2-dependent activation of the NF-&#954;B pathway</article-title><source>bioRxiv</source><year>2021</year><pub-id pub-id-type="doi">10.1101/2021.03.16.435700</pub-id><pub-id pub-id-type="pmcid">PMC8709575</pub-id><pub-id pub-id-type="pmid">34866574</pub-id></element-citation></ref><ref id="B50-viruses-13-02302"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sariol</surname><given-names>A.</given-names></name><name name-style="western"><surname>Perlman</surname><given-names>S.</given-names></name></person-group><article-title>SARS-CoV-2 takes its Toll</article-title><source>Nat. Immunol.</source><year>2021</year><volume>22</volume><fpage>801</fpage><lpage>802</lpage><pub-id pub-id-type="doi">10.1038/s41590-021-00962-w</pub-id><pub-id pub-id-type="pmid">34103714</pub-id><pub-id pub-id-type="pmcid">PMC8238877</pub-id></element-citation></ref><ref id="B51-viruses-13-02302"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Conti</surname><given-names>P.</given-names></name><name name-style="western"><surname>Caraffa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tete</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gallenga</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Ross</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kritas</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Frydas</surname><given-names>I.</given-names></name><name name-style="western"><surname>Younes</surname><given-names>A.</given-names></name><name name-style="western"><surname>Di Emidio</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ronconi</surname><given-names>G.</given-names></name></person-group><article-title>Mast cells activated by SARS-CoV-2 release histamine which increases IL-1 levels causing cytokine storm and inflammatory reaction in COVID-19</article-title><source>J. Biol. Regul. Homeost. Agents</source><year>2020</year><volume>34</volume><fpage>1629</fpage><lpage>1632</lpage><pub-id pub-id-type="pmid">32945158</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.23812/20-2EDIT</pub-id></element-citation></ref><ref id="B52-viruses-13-02302"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gebremeskel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schanin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Coyle</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Butuci</surname><given-names>M.</given-names></name><name name-style="western"><surname>Luu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Brock</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>A.</given-names></name><name name-style="western"><surname>Leung</surname><given-names>J.</given-names></name><name name-style="western"><surname>Korver</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Mast Cell and Eosinophil Activation Are Associated With COVID-19 and TLR-Mediated Viral Inflammation: Implications for an Anti-Siglec-8 Antibody</article-title><source>Front. Immunol.</source><year>2021</year><volume>12</volume><fpage>641</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2021.650331</pub-id><pub-id pub-id-type="pmid">33777047</pub-id><pub-id pub-id-type="pmcid">PMC7988091</pub-id></element-citation></ref><ref id="B53-viruses-13-02302"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahmad</surname><given-names>R.</given-names></name><name name-style="western"><surname>Al-Mass</surname><given-names>A.</given-names></name><name name-style="western"><surname>Atizado</surname><given-names>V.</given-names></name><name name-style="western"><surname>Al-Hubail</surname><given-names>A.</given-names></name><name name-style="western"><surname>Al-Ghimlas</surname><given-names>F.</given-names></name><name name-style="western"><surname>Al-Arouj</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bennakhi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dermime</surname><given-names>S.</given-names></name><name name-style="western"><surname>Behbehani</surname><given-names>K.</given-names></name></person-group><article-title>Elevated expression of the toll like receptors 2 and 4 in obese individuals: Its significance for obesity-induced inflammation</article-title><source>J. Inflamm.</source><year>2012</year><volume>9</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1186/1476-9255-9-48</pub-id><pub-id pub-id-type="pmcid">PMC3542010</pub-id><pub-id pub-id-type="pmid">23191980</pub-id></element-citation></ref><ref id="B54-viruses-13-02302"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cuevas</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Potter</surname><given-names>J.J.</given-names></name></person-group><article-title>Increased TLR/MyD88 signaling in patients with obesity: Is there a link to COVID-19 disease severity?</article-title><source>Int. J. Obes.</source><year>2021</year><volume>45</volume><fpage>1152</fpage><lpage>1154</lpage><pub-id pub-id-type="doi">10.1038/s41366-021-00768-8</pub-id><pub-id pub-id-type="pmcid">PMC7909368</pub-id><pub-id pub-id-type="pmid">33637950</pub-id></element-citation></ref><ref id="B55-viruses-13-02302"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Englmeier</surname><given-names>L.</given-names></name></person-group><article-title>A theory on SARS-COV-2 susceptibility: Reduced TLR7-activity as a mechanistic link between men, obese and elderly</article-title><source>J. Biol. Regul. Homeost. Agents</source><year>2020</year><volume>34</volume><fpage>1125</fpage><lpage>1129</lpage><pub-id pub-id-type="pmid">32456409</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.23812/20-221-L-49</pub-id></element-citation></ref><ref id="B56-viruses-13-02302"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Der Made</surname><given-names>C.I.</given-names></name><name name-style="western"><surname>Simons</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schuurs-Hoeijmakers</surname><given-names>J.</given-names></name><name name-style="western"><surname>Heuvel</surname><given-names>G.V.D.</given-names></name><name name-style="western"><surname>Mantere</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kersten</surname><given-names>S.</given-names></name><name name-style="western"><surname>Van Deuren</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Steehouwer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Van Reijmersdal</surname><given-names>S.V.</given-names></name><name name-style="western"><surname>Jaeger</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Presence of Genetic Variants Among Young Men With Severe COVID-19</article-title><source>JAMA</source><year>2020</year><volume>324</volume><fpage>663</fpage><lpage>673</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.13719</pub-id><pub-id pub-id-type="pmid">32706371</pub-id><pub-id pub-id-type="pmcid">PMC7382021</pub-id></element-citation></ref><ref id="B57-viruses-13-02302"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fallerini</surname><given-names>C.</given-names></name><name name-style="western"><surname>Daga</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mantovani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Benetti</surname><given-names>E.</given-names></name><name name-style="western"><surname>Picchiotti</surname><given-names>N.</given-names></name><name name-style="western"><surname>Francisci</surname><given-names>D.</given-names></name><name name-style="western"><surname>Paciosi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Schiaroli</surname><given-names>E.</given-names></name><name name-style="western"><surname>Baldassarri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fava</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Association of Toll-like receptor 7 variants with life-threatening COVID-19 disease in males: Findings from a nested case-control study</article-title><source>eLife</source><year>2021</year><volume>10</volume><fpage>e67569</fpage><pub-id pub-id-type="doi">10.7554/eLife.67569</pub-id><pub-id pub-id-type="pmid">33650967</pub-id><pub-id pub-id-type="pmcid">PMC7987337</pub-id></element-citation></ref><ref id="B58-viruses-13-02302"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Severa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Diotti</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Etna</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Rizzo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Fiore</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ricci</surname><given-names>D.</given-names></name><name name-style="western"><surname>Iannetta</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sinigaglia</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lodi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mancini</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Differential plasmacytoid dendritic cell phenotype and type I Interferon response in asymptomatic and severe COVID-19 infection</article-title><source>PLoS Pathog.</source><year>2021</year><volume>17</volume><elocation-id>e1009878</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1009878</pub-id><pub-id pub-id-type="pmid">34473805</pub-id><pub-id pub-id-type="pmcid">PMC8412261</pub-id></element-citation></ref><ref id="B59-viruses-13-02302"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>V.</given-names></name><name name-style="western"><surname>Shannon</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>X.-S.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.-H.</given-names></name><name name-style="western"><surname>Tebbutt</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Kollmann</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Fish</surname><given-names>E.N.</given-names></name></person-group><article-title>Interferon-&#945;2b Treatment for COVID-19</article-title><source>Front. Immunol.</source><year>2020</year><volume>11</volume><fpage>1061</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2020.01061</pub-id><pub-id pub-id-type="pmid">32574262</pub-id><pub-id pub-id-type="pmcid">PMC7242746</pub-id></element-citation></ref><ref id="B60-viruses-13-02302"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sohn</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.-G.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Cheon</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>I.S.</given-names></name><name name-style="western"><surname>Silwal</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Paik</surname><given-names>S.</given-names></name><etal/></person-group><article-title>COVID-19 Patients Upregulate Toll-like Receptor 4-mediated Inflammatory Signaling That Mimics Bacterial Sepsis</article-title><source>J. Korean Med. Sci.</source><year>2020</year><volume>35</volume><fpage>e343</fpage><pub-id pub-id-type="doi">10.3346/jkms.2020.35.e343</pub-id><pub-id pub-id-type="pmid">32989935</pub-id><pub-id pub-id-type="pmcid">PMC7521960</pub-id></element-citation></ref><ref id="B61-viruses-13-02302"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aguida</surname><given-names>B.</given-names></name><name name-style="western"><surname>Pooam</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jourdan</surname><given-names>N.</given-names></name></person-group><article-title>Infrared light therapy relieves TLR-4 dependent hyper-inflammation of the type induced by COVID-19</article-title><source>Commun. Integr. Biol.</source><year>2021</year><volume>14</volume><fpage>200</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1080/19420889.2021.1965718</pub-id><pub-id pub-id-type="pmid">34552685</pub-id><pub-id pub-id-type="pmcid">PMC8451450</pub-id></element-citation></ref><ref id="B62-viruses-13-02302"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pessoa</surname><given-names>N.L.</given-names></name><name name-style="western"><surname>Bentes</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>de Carvalho</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>T.B.D.S.</given-names></name><name name-style="western"><surname>Alves</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Reis</surname><given-names>E.V.D.S.</given-names></name><name name-style="western"><surname>Rodrigues</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Kroon</surname><given-names>E.G.</given-names></name><name name-style="western"><surname>Campos</surname><given-names>M.A.</given-names></name></person-group><article-title>Case report: Hepatitis in a child infected with SARS-CoV-2 presenting toll-like receptor 7 Gln11Leu single nucleotide polymorphism</article-title><source>Virol. J.</source><year>2021</year><volume>18</volume><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1186/s12985-021-01656-3</pub-id><pub-id pub-id-type="pmid">34482844</pub-id><pub-id pub-id-type="pmcid">PMC8418785</pub-id></element-citation></ref><ref id="B63-viruses-13-02302"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Du</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China</article-title><source>JAMA Intern. Med.</source><year>2020</year><volume>180</volume><fpage>934</fpage><lpage>943</lpage><pub-id pub-id-type="doi">10.1001/jamainternmed.2020.0994</pub-id><pub-id pub-id-type="pmid">32167524</pub-id><pub-id pub-id-type="pmcid">PMC7070509</pub-id></element-citation></ref><ref id="B64-viruses-13-02302"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Curatola</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chiaretti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ferretti</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bersani</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lucchetti</surname><given-names>D.</given-names></name><name name-style="western"><surname>Capossela</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sgambato</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gatto</surname><given-names>A.</given-names></name></person-group><article-title>Cytokine Response to SARS-CoV-2 Infection in Children</article-title><source>Viruses</source><year>2021</year><volume>13</volume><elocation-id>1868</elocation-id><pub-id pub-id-type="doi">10.3390/v13091868</pub-id><pub-id pub-id-type="pmid">34578450</pub-id><pub-id pub-id-type="pmcid">PMC8473005</pub-id></element-citation></ref><ref id="B65-viruses-13-02302"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scully</surname><given-names>E.P.</given-names></name><name name-style="western"><surname>Haverfield</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ursin</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Tannenbaum</surname><given-names>C.</given-names></name><name name-style="western"><surname>Klein</surname><given-names>S.L.</given-names></name></person-group><article-title>Considering how biological sex impacts immune responses and COVID-19 outcomes</article-title><source>Nat. Rev. Immunol.</source><year>2020</year><volume>20</volume><fpage>442</fpage><lpage>447</lpage><pub-id pub-id-type="doi">10.1038/s41577-020-0348-8</pub-id><pub-id pub-id-type="pmid">32528136</pub-id><pub-id pub-id-type="pmcid">PMC7288618</pub-id></element-citation></ref><ref id="B66-viruses-13-02302"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Souyris</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cenac</surname><given-names>C.</given-names></name><name name-style="western"><surname>Azar</surname><given-names>P.</given-names></name><name name-style="western"><surname>Daviaud</surname><given-names>D.</given-names></name><name name-style="western"><surname>Canivet</surname><given-names>A.</given-names></name><name name-style="western"><surname>Grunenwald</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pienkowski</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chaumeil</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mej&#237;a</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Gu&#233;ry</surname><given-names>J.-C.</given-names></name></person-group><article-title>TLR7 escapes X chromosome inactivation in immune cells</article-title><source>Sci. Immunol.</source><year>2018</year><volume>3</volume><pub-id pub-id-type="doi">10.1126/sciimmunol.aap8855</pub-id><pub-id pub-id-type="pmid">29374079</pub-id></element-citation></ref><ref id="B67-viruses-13-02302"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Goldstein</surname><given-names>D.R.</given-names></name></person-group><article-title>Impact of aging on viral infections</article-title><source>Microbes Infect.</source><year>2010</year><volume>12</volume><fpage>1120</fpage><lpage>1124</lpage><pub-id pub-id-type="doi">10.1016/j.micinf.2010.08.009</pub-id><pub-id pub-id-type="pmid">20849976</pub-id><pub-id pub-id-type="pmcid">PMC2998572</pub-id></element-citation></ref><ref id="B68-viruses-13-02302"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oh</surname><given-names>S.-J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>O.S.</given-names></name></person-group><article-title>Aging and the Immune System: The Impact of Immunosenescence on Viral Infection, Immunity and Vaccine Immunogenicity</article-title><source>Immune Netw.</source><year>2019</year><volume>19</volume><fpage>e37</fpage><pub-id pub-id-type="doi">10.4110/in.2019.19.e37</pub-id><pub-id pub-id-type="pmid">31921467</pub-id><pub-id pub-id-type="pmcid">PMC6943173</pub-id></element-citation></ref><ref id="B69-viruses-13-02302"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bartleson</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Radenkovic</surname><given-names>D.</given-names></name><name name-style="western"><surname>Covarrubias</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Furman</surname><given-names>D.</given-names></name><name name-style="western"><surname>Winer</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Verdin</surname><given-names>E.</given-names></name></person-group><article-title>SARS-CoV-2, COVID-19 and the aging immune system</article-title><source>Nat. Aging</source><year>2021</year><volume>1</volume><fpage>769</fpage><lpage>782</lpage><pub-id pub-id-type="doi">10.1038/s43587-021-00114-7</pub-id><pub-id pub-id-type="pmid">34746804</pub-id><pub-id pub-id-type="pmcid">PMC8570568</pub-id></element-citation></ref><ref id="B70-viruses-13-02302"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Williamson</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Bhaskaran</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bacon</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bates</surname><given-names>C.</given-names></name><name name-style="western"><surname>Morton</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Curtis</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Mehrkar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>D.</given-names></name><name name-style="western"><surname>Inglesby</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Factors associated with COVID-19-related death using OpenSAFELY</article-title><source>Nature</source><year>2020</year><volume>584</volume><fpage>430</fpage><lpage>436</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2521-4</pub-id><pub-id pub-id-type="pmid">32640463</pub-id><pub-id pub-id-type="pmcid">PMC7611074</pub-id></element-citation></ref><ref id="B71-viruses-13-02302"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Richardson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hirsch</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Narasimhan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Crawford</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>McGinn</surname><given-names>T.</given-names></name><name name-style="western"><surname>Davidson</surname><given-names>K.W.</given-names></name><collab>Northwell COVID-19 Research Consortium</collab></person-group><article-title>Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized with COVID-19 in the New York City Area</article-title><source>JAMA</source><year>2020</year><volume>323</volume><fpage>2052</fpage><lpage>2059</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.6775</pub-id><pub-id pub-id-type="pmid">32320003</pub-id><pub-id pub-id-type="pmcid">PMC7177629</pub-id></element-citation></ref><ref id="B72-viruses-13-02302"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Su</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>D.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lausted</surname><given-names>C.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Voillet</surname><given-names>V.</given-names></name><name name-style="western"><surname>Duvvuri</surname><given-names>V.R.</given-names></name><name name-style="western"><surname>Scherler</surname><given-names>K.</given-names></name><name name-style="western"><surname>Troisch</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19</article-title><source>Cell</source><year>2020</year><volume>183</volume><fpage>1479</fpage><lpage>1495</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.10.037</pub-id><pub-id pub-id-type="pmid">33171100</pub-id><pub-id pub-id-type="pmcid">PMC7598382</pub-id></element-citation></ref><ref id="B73-viruses-13-02302"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lucas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>P.</given-names></name><name name-style="western"><surname>Klein</surname><given-names>J.</given-names></name><name name-style="western"><surname>Castro</surname><given-names>T.B.R.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sundaram</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ellingson</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>T.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Israelow</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Longitudinal analyses reveal immunological misfiring in severe COVID-19</article-title><source>Nat. Cell Biol.</source><year>2020</year><volume>584</volume><fpage>463</fpage><lpage>469</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2588-y</pub-id><pub-id pub-id-type="pmcid">PMC7477538</pub-id><pub-id pub-id-type="pmid">32717743</pub-id></element-citation></ref><ref id="B74-viruses-13-02302"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>T.</given-names></name><name name-style="western"><surname>Du</surname><given-names>S.-Y.</given-names></name><name name-style="western"><surname>Son</surname><given-names>M.</given-names></name><name name-style="western"><surname>Diamond</surname><given-names>B.</given-names></name></person-group><article-title>HIF-1&#945; is a negative regulator of interferon regulatory factors: Implications for interferon production by hypoxic monocytes</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2021</year><volume>118</volume><fpage>e2106017118</fpage><pub-id pub-id-type="doi">10.1073/pnas.2106017118</pub-id><pub-id pub-id-type="pmid">34108245</pub-id><pub-id pub-id-type="pmcid">PMC8256008</pub-id></element-citation></ref><ref id="B75-viruses-13-02302"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taniguchi-Ponciano</surname><given-names>K.</given-names></name><name name-style="western"><surname>Vadillo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mayani</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gonzalez-Bonilla</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Torres</surname><given-names>J.</given-names></name><name name-style="western"><surname>Majluf</surname><given-names>A.</given-names></name><name name-style="western"><surname>Flores-Padilla</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wacher-Rodarte</surname><given-names>N.</given-names></name><name name-style="western"><surname>Galan</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Ferat-Osorio</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Increased expression of hypoxia-induced factor 1&#945; mRNA and its related genes in myeloid blood cells from critically ill COVID-19 patients</article-title><source>Ann. Med.</source><year>2021</year><volume>53</volume><fpage>197</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1080/07853890.2020.1858234</pub-id><pub-id pub-id-type="pmid">33345622</pub-id><pub-id pub-id-type="pmcid">PMC7784832</pub-id></element-citation></ref><ref id="B76-viruses-13-02302"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hadjadj</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yatim</surname><given-names>N.</given-names></name><name name-style="western"><surname>Barnabei</surname><given-names>L.</given-names></name><name name-style="western"><surname>Corneau</surname><given-names>A.</given-names></name><name name-style="western"><surname>Boussier</surname><given-names>J.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>N.</given-names></name><name name-style="western"><surname>P&#233;r&#233;</surname><given-names>H.</given-names></name><name name-style="western"><surname>Charbit</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bondet</surname><given-names>V.</given-names></name><name name-style="western"><surname>Chenevier-Gobeaux</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients</article-title><source>Science</source><year>2020</year><volume>369</volume><fpage>718</fpage><lpage>724</lpage><pub-id pub-id-type="doi">10.1126/science.abc6027</pub-id><pub-id pub-id-type="pmid">32661059</pub-id><pub-id pub-id-type="pmcid">PMC7402632</pub-id></element-citation></ref><ref id="B77-viruses-13-02302"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loffredo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lucero</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>D.-Y.</given-names></name><name name-style="western"><surname>O&#8217;Connell</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bergqvist</surname><given-names>S.</given-names></name><name name-style="western"><surname>Munawar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bandara</surname><given-names>A.</given-names></name><name name-style="western"><surname>De Graef</surname><given-names>S.</given-names></name><name name-style="western"><surname>Weeks</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Douam</surname><given-names>F.</given-names></name><etal/></person-group><article-title>The in-vitro effect of famotidine on SARS-CoV-2 proteases and virus replication</article-title><source>Sci. Rep.</source><year>2021</year><volume>11</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1038/s41598-021-84782-w</pub-id><pub-id pub-id-type="pmid">33686143</pub-id><pub-id pub-id-type="pmcid">PMC7940615</pub-id></element-citation></ref><ref id="B78-viruses-13-02302"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Freedberg</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Conigliaro</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Tracey</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Callahan</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Abrams</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Sobieszczyk</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Markowitz</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>A.</given-names></name><name name-style="western"><surname>O&#8217;Donnell</surname><given-names>M.R.</given-names></name><etal/></person-group><article-title>Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study</article-title><source>Gastroenterology</source><year>2020</year><volume>159</volume><fpage>1129</fpage><lpage>1131</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2020.05.053</pub-id><pub-id pub-id-type="pmid">32446698</pub-id><pub-id pub-id-type="pmcid">PMC7242191</pub-id></element-citation></ref><ref id="B79-viruses-13-02302"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mather</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Seip</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>McKay</surname><given-names>R.G.</given-names></name></person-group><article-title>Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients with COVID-19</article-title><source>Am. J. Gastroenterol.</source><year>2020</year><volume>115</volume><fpage>1617</fpage><lpage>1623</lpage><pub-id pub-id-type="doi">10.14309/ajg.0000000000000832</pub-id><pub-id pub-id-type="pmid">32852338</pub-id><pub-id pub-id-type="pmcid">PMC7473796</pub-id></element-citation></ref><ref id="B80-viruses-13-02302"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mukherjee</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bhattacharya</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bojkova</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mehdipour</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Cheung</surname><given-names>H.H.-Y.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>K.-B.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>W.-L.</given-names></name><name name-style="western"><surname>Cinatl</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Famotidine inhibits toll-like receptor 3-mediated inflammatory signaling in SARS-CoV-2 infection</article-title><source>J. Biol. Chem.</source><year>2021</year><volume>297</volume><fpage>100925</fpage><pub-id pub-id-type="doi">10.1016/j.jbc.2021.100925</pub-id><pub-id pub-id-type="pmid">34214498</pub-id><pub-id pub-id-type="pmcid">PMC8241579</pub-id></element-citation></ref><ref id="B81-viruses-13-02302"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tiwari</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>D.</given-names></name><name name-style="western"><surname>Carlin</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Rana</surname><given-names>T.M.</given-names></name></person-group><article-title>Revealing Tissue-Specific SARS-CoV-2 Infection and Host Responses using Human Stem Cell-Derived Lung and Cerebral Organoids</article-title><source>Stem Cell Rep.</source><year>2021</year><volume>16</volume><fpage>437</fpage><lpage>445</lpage><pub-id pub-id-type="doi">10.1016/j.stemcr.2021.02.005</pub-id><pub-id pub-id-type="pmcid">PMC7879814</pub-id><pub-id pub-id-type="pmid">33631122</pub-id></element-citation></ref><ref id="B82-viruses-13-02302"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salaris</surname><given-names>C.</given-names></name><name name-style="western"><surname>Scarpa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Elli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bertolini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Guglielmetti</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pregliasco</surname><given-names>F.</given-names></name><name name-style="western"><surname>Blandizzi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Brun</surname><given-names>P.</given-names></name><name name-style="western"><surname>Castagliuolo</surname><given-names>I.</given-names></name></person-group><article-title>Protective Effects of Lactoferrin against SARS-CoV-2 Infection In Vitro</article-title><source>Nutrients</source><year>2021</year><volume>13</volume><elocation-id>328</elocation-id><pub-id pub-id-type="doi">10.3390/nu13020328</pub-id><pub-id pub-id-type="pmid">33498631</pub-id><pub-id pub-id-type="pmcid">PMC7911668</pub-id></element-citation></ref><ref id="B83-viruses-13-02302"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blanco-Melo</surname><given-names>D.</given-names></name><name name-style="western"><surname>Nilsson-Payant</surname><given-names>B.E.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.-C.</given-names></name><name name-style="western"><surname>Uhl</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hoagland</surname><given-names>D.</given-names></name><name name-style="western"><surname>M&#248;ller</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jordan</surname><given-names>T.X.</given-names></name><name name-style="western"><surname>Oishi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Panis</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sachs</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19</article-title><source>Cell</source><year>2020</year><volume>181</volume><fpage>1036</fpage><lpage>1045</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.04.026</pub-id><pub-id pub-id-type="pmid">32416070</pub-id><pub-id pub-id-type="pmcid">PMC7227586</pub-id></element-citation></ref><ref id="B84-viruses-13-02302"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Venet</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ribeiro</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>D&#233;cembre</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bellomo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Joshi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Villard</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cluet</surname><given-names>D.</given-names></name><name name-style="western"><surname>Perret</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pescamona</surname><given-names>R.</given-names></name><name name-style="western"><surname>Paidassi</surname><given-names>H.</given-names></name><etal/></person-group><article-title>SARS-CoV-2 infected cells trigger an acute antiviral response mediated by Plasmacytoid dendritic cells in mild but not severe COVID-19 patients</article-title><source>medRxiv</source><year>2021</year><pub-id pub-id-type="doi">10.1101/2021.09.01.21262969</pub-id></element-citation></ref><ref id="B85-viruses-13-02302"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bastard</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rosen</surname><given-names>L.B.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Michailidis</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hoffmann</surname><given-names>H.-H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Dorgham</surname><given-names>K.</given-names></name><name name-style="western"><surname>Philippot</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Rosain</surname><given-names>J.</given-names></name><name name-style="western"><surname>B&#233;ziat</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Auto-antibodies against type I IFNs in patients with life-threatening COVID-19</article-title><source>Science</source><year>2020</year><volume>370</volume><pub-id pub-id-type="doi">10.1126/science.abd4585</pub-id><pub-id pub-id-type="pmid">32972996</pub-id><pub-id pub-id-type="pmcid">PMC7857397</pub-id></element-citation></ref><ref id="B86-viruses-13-02302"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>A.</given-names></name><name name-style="western"><surname>Iwasaki</surname><given-names>A.</given-names></name></person-group><article-title>Type I and Type III Interferons&#8212;Induction, Signaling, Evasion, and Application to Combat COVID-19</article-title><source>Cell Host Microbe</source><year>2020</year><volume>27</volume><fpage>870</fpage><lpage>878</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2020.05.008</pub-id><pub-id pub-id-type="pmid">32464097</pub-id><pub-id pub-id-type="pmcid">PMC7255347</pub-id></element-citation></ref><ref id="B87-viruses-13-02302"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lei</surname><given-names>X.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Activation and evasion of type I interferon responses by SARS-CoV-2</article-title><source>Nat. Commun.</source><year>2020</year><volume>11</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1038/s41467-020-17665-9</pub-id><pub-id pub-id-type="pmid">32733001</pub-id><pub-id pub-id-type="pmcid">PMC7392898</pub-id></element-citation></ref><ref id="B88-viruses-13-02302"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhuang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>P.</given-names></name></person-group><article-title>SARS-CoV-2 ORF9b antagonizes type I and III interferons by targeting multiple components of the RIG-I/MDA-5&#8211;MAVS, TLR3&#8211;TRIF, and cGAS&#8211;STING signaling pathways</article-title><source>J. Med. Virol.</source><year>2021</year><volume>93</volume><fpage>5376</fpage><lpage>5389</lpage><pub-id pub-id-type="doi">10.1002/jmv.27050</pub-id><pub-id pub-id-type="pmid">33913550</pub-id><pub-id pub-id-type="pmcid">PMC8242602</pub-id></element-citation></ref><ref id="B89-viruses-13-02302"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schreiber</surname><given-names>G.</given-names></name></person-group><article-title>The Role of Type I Interferons in the Pathogenesis and Treatment of COVID-19</article-title><source>Front. Immunol.</source><year>2020</year><volume>11</volume><fpage>595739</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2020.595739</pub-id><pub-id pub-id-type="pmid">33117408</pub-id><pub-id pub-id-type="pmcid">PMC7561359</pub-id></element-citation></ref><ref id="B90-viruses-13-02302"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J.-Y.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>C.-H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>Y.-J.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ge</surname><given-names>X.-Y.</given-names></name></person-group><article-title>The ORF6, ORF8 and nucleocapsid proteins of SARS-CoV-2 inhibit type I interferon signaling pathway</article-title><source>Virus Res.</source><year>2020</year><volume>286</volume><fpage>198074</fpage><pub-id pub-id-type="doi">10.1016/j.virusres.2020.198074</pub-id><pub-id pub-id-type="pmid">32589897</pub-id><pub-id pub-id-type="pmcid">PMC7309931</pub-id></element-citation></ref><ref id="B91-viruses-13-02302"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sui</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q.</given-names></name></person-group><article-title>SARS-CoV-2 Membrane Protein Inhibits Type I Interferon Production Through Ubiquitin-Mediated Degradation of TBK1</article-title><source>Front. Immunol.</source><year>2021</year><volume>12</volume><fpage>662989</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2021.662989</pub-id><pub-id pub-id-type="pmid">34084167</pub-id><pub-id pub-id-type="pmcid">PMC8168463</pub-id></element-citation></ref><ref id="B92-viruses-13-02302"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ricci</surname><given-names>D.</given-names></name><name name-style="western"><surname>Etna</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rizzo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sandini</surname><given-names>S.</given-names></name><name name-style="western"><surname>Severa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Coccia</surname><given-names>E.</given-names></name></person-group><article-title>Innate Immune Response to SARS-CoV-2 Infection: From Cells to Soluble Mediators</article-title><source>Int. J. Mol. Sci.</source><year>2021</year><volume>22</volume><elocation-id>7017</elocation-id><pub-id pub-id-type="doi">10.3390/ijms22137017</pub-id><pub-id pub-id-type="pmid">34209845</pub-id><pub-id pub-id-type="pmcid">PMC8268312</pub-id></element-citation></ref><ref id="B93-viruses-13-02302"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mullins</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Vasilakos</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Deschler</surname><given-names>K.</given-names></name><name name-style="western"><surname>Grigsby</surname><given-names>I.</given-names></name><name name-style="western"><surname>Gillis</surname><given-names>P.</given-names></name><name name-style="western"><surname>John</surname><given-names>J.</given-names></name><name name-style="western"><surname>Elder</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Swales</surname><given-names>J.</given-names></name><name name-style="western"><surname>Timosenko</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies</article-title><source>J. Immunother. Cancer</source><year>2019</year><volume>7</volume><fpage>1</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1186/s40425-019-0724-8</pub-id><pub-id pub-id-type="pmid">31511088</pub-id><pub-id pub-id-type="pmcid">PMC6739946</pub-id></element-citation></ref><ref id="B94-viruses-13-02302"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Surendran</surname><given-names>N.</given-names></name><name name-style="western"><surname>Simmons</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pichichero</surname><given-names>M.E.</given-names></name></person-group><article-title>TLR agonist combinations that stimulate Th type I polarizing responses from human neonates</article-title><source>Innate Immun.</source><year>2018</year><volume>24</volume><fpage>240</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1177/1753425918771178</pub-id><pub-id pub-id-type="pmid">29673285</pub-id><pub-id pub-id-type="pmcid">PMC6830928</pub-id></element-citation></ref><ref id="B95-viruses-13-02302"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hennessy</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Parker</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>O&#8217;Neill</surname><given-names>L.</given-names></name></person-group><article-title>Targeting Toll-like receptors: Emerging therapeutics?</article-title><source>Nat. Rev. Drug Discov.</source><year>2010</year><volume>9</volume><fpage>293</fpage><lpage>307</lpage><pub-id pub-id-type="doi">10.1038/nrd3203</pub-id><pub-id pub-id-type="pmid">20380038</pub-id></element-citation></ref><ref id="B96-viruses-13-02302"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kayesh</surname><given-names>M.E.H.</given-names></name><name name-style="western"><surname>Kohara</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tsukiyama-Kohara</surname><given-names>K.</given-names></name></person-group><article-title>Toll-Like Receptor Response to Hepatitis B Virus Infection and Potential of TLR Agonists as Immunomodulators for Treating Chronic Hepatitis B: An Overview</article-title><source>Int. J. Mol. Sci.</source><year>2021</year><volume>22</volume><elocation-id>10462</elocation-id><pub-id pub-id-type="doi">10.3390/ijms221910462</pub-id><pub-id pub-id-type="pmid">34638802</pub-id><pub-id pub-id-type="pmcid">PMC8508807</pub-id></element-citation></ref><ref id="B97-viruses-13-02302"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alderson</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>McGowan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Baldridge</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Probst</surname><given-names>P.</given-names></name></person-group><article-title>TLR4 agonists as immunomodulatory agents</article-title><source>J. Endotoxin Res.</source><year>2006</year><volume>12</volume><fpage>313</fpage><lpage>319</lpage><pub-id pub-id-type="doi">10.1177/09680519060120050701</pub-id><pub-id pub-id-type="pmid">17059695</pub-id></element-citation></ref><ref id="B98-viruses-13-02302"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baldridge</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>McGowan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Cluff</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mossman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>D.</given-names></name><name name-style="western"><surname>Persing</surname><given-names>D.</given-names></name></person-group><article-title>Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents</article-title><source>Expert Opin. Biol. Ther.</source><year>2004</year><volume>4</volume><fpage>1129</fpage><lpage>1138</lpage><pub-id pub-id-type="doi">10.1517/14712598.4.7.1129</pub-id><pub-id pub-id-type="pmid">15268679</pub-id></element-citation></ref><ref id="B99-viruses-13-02302"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Evans</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Cluff</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Lacy</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Persing</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Baldridge</surname><given-names>J.R.</given-names></name></person-group><article-title>Enhancement of antigen-specific immunity via the TLR4 ligands MPL&#8482; adjuvant and Ribi.529</article-title><source>Expert Rev. Vaccines</source><year>2003</year><volume>2</volume><fpage>219</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.1586/14760584.2.2.219</pub-id><pub-id pub-id-type="pmid">12899573</pub-id></element-citation></ref><ref id="B100-viruses-13-02302"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>S&#225;nchez-Ram&#243;n</surname><given-names>S.</given-names></name><name name-style="western"><surname>Conejero</surname><given-names>L.</given-names></name><name name-style="western"><surname>Netea</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Sancho</surname><given-names>D.</given-names></name><name name-style="western"><surname>Palomares</surname><given-names>&#211;.</given-names></name><name name-style="western"><surname>Subiza</surname><given-names>J.L.</given-names></name></person-group><article-title>Trained Immunity-Based Vaccines: A New Paradigm for the Development of Broad-Spectrum Anti-infectious Formulations</article-title><source>Front. Immunol.</source><year>2018</year><volume>9</volume><fpage>2936</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.02936</pub-id><pub-id pub-id-type="pmid">30619296</pub-id><pub-id pub-id-type="pmcid">PMC6304371</pub-id></element-citation></ref><ref id="B101-viruses-13-02302"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reed</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Orr</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>C.</given-names></name></person-group><article-title>Key roles of adjuvants in modern vaccines</article-title><source>Nat. Med.</source><year>2013</year><volume>19</volume><fpage>1597</fpage><lpage>1608</lpage><pub-id pub-id-type="doi">10.1038/nm.3409</pub-id><pub-id pub-id-type="pmid">24309663</pub-id></element-citation></ref><ref id="B102-viruses-13-02302"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ro&#223;mann</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bagola</surname><given-names>K.</given-names></name><name name-style="western"><surname>Stephen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gerards</surname><given-names>A.-L.</given-names></name><name name-style="western"><surname>Walber</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ullrich</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sch&#252;lke</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kamp</surname><given-names>C.</given-names></name><name name-style="western"><surname>Spreitzer</surname><given-names>I.</given-names></name><name name-style="western"><surname>Hasan</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Distinct single-component adjuvants steer human DC-mediated T-cell polarization via Toll-like receptor signaling toward a potent antiviral immune response</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2021</year><volume>118</volume><fpage>e2103651118</fpage><pub-id pub-id-type="doi">10.1073/pnas.2103651118</pub-id><pub-id pub-id-type="pmid">34561306</pub-id><pub-id pub-id-type="pmcid">PMC8488681</pub-id></element-citation></ref><ref id="B103-viruses-13-02302"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jeong</surname><given-names>S.-K.</given-names></name><name name-style="western"><surname>Heo</surname><given-names>Y.-K.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>J.-H.</given-names></name><name name-style="western"><surname>Ham</surname><given-names>S.-J.</given-names></name><name name-style="western"><surname>Yum</surname><given-names>J.-S.</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>B.-C.</given-names></name><name name-style="western"><surname>Song</surname><given-names>C.-S.</given-names></name><name name-style="western"><surname>Chun</surname><given-names>E.-Y.</given-names></name></person-group><article-title>COVID-19 Subunit Vaccine with a Combination of TLR1/2 and TLR3 Agonists Induces Robust and Protective Immunity</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><elocation-id>957</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines9090957</pub-id><pub-id pub-id-type="pmid">34579194</pub-id><pub-id pub-id-type="pmcid">PMC8473206</pub-id></element-citation></ref><ref id="B104-viruses-13-02302"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Proud</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Tsitoura</surname><given-names>D.</given-names></name><name name-style="western"><surname>Watson</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Chua</surname><given-names>B.Y.</given-names></name><name name-style="western"><surname>Aram</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Bewley</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Cavell</surname><given-names>B.E.</given-names></name><name name-style="western"><surname>Cobb</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dowall</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fotheringham</surname><given-names>S.A.</given-names></name><etal/></person-group><article-title>Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model</article-title><source>EBioMedicine</source><year>2021</year><volume>63</volume><fpage>103153</fpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2020.103153</pub-id><pub-id pub-id-type="pmid">33279857</pub-id><pub-id pub-id-type="pmcid">PMC7711201</pub-id></element-citation></ref><ref id="B105-viruses-13-02302"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kesharwani</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Kuppast</surname><given-names>B.</given-names></name><name name-style="western"><surname>Rajput</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bakkari</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Tummala</surname><given-names>H.</given-names></name></person-group><article-title>Discovery of inulin acetate as a novel immune-active polymer and vaccine adjuvant: Synthesis, material characterization, and biological evaluation as a toll-like receptor-4 agonist</article-title><source>J. Mater. Chem. B</source><year>2016</year><volume>4</volume><fpage>7950</fpage><lpage>7960</lpage><pub-id pub-id-type="doi">10.1039/C6TB02181F</pub-id><pub-id pub-id-type="pmid">32263785</pub-id></element-citation></ref><ref id="B106-viruses-13-02302"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bakkari</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Valiveti</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Kaushik</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Tummala</surname><given-names>H.</given-names></name></person-group><article-title>Toll-like Receptor-4 (TLR4) Agonist-Based Intranasal Nanovaccine Delivery System for Inducing Systemic and Mucosal Immunity</article-title><source>Mol. Pharm.</source><year>2021</year><volume>18</volume><fpage>2233</fpage><lpage>2241</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.0c01256</pub-id><pub-id pub-id-type="pmid">34010002</pub-id></element-citation></ref><ref id="B107-viruses-13-02302"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C.</given-names></name></person-group><article-title>The immune responses of HLA-A*0201 restricted SARS-CoV S peptide-specific CD8+ T cells are augmented in varying degrees by CpG ODN, PolyI:C and R848</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><fpage>6670</fpage><lpage>6678</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.06.100</pub-id><pub-id pub-id-type="pmid">21745520</pub-id><pub-id pub-id-type="pmcid">PMC7115397</pub-id></element-citation></ref><ref id="B108-viruses-13-02302"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kared</surname><given-names>H.</given-names></name><name name-style="western"><surname>Redd</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Bloch</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Bonny</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Sumatoh</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Kairi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Carbajo</surname><given-names>D.</given-names></name><name name-style="western"><surname>Abel</surname><given-names>B.</given-names></name><name name-style="western"><surname>Newell</surname><given-names>E.W.</given-names></name><name name-style="western"><surname>Bettinotti</surname><given-names>M.P.</given-names></name><etal/></person-group><article-title>SARS-CoV-2&#8211;specific CD8+ T cell responses in convalescent COVID-19 individuals</article-title><source>J. Clin. Investig.</source><year>2021</year><volume>131</volume><pub-id pub-id-type="doi">10.1172/JCI145476</pub-id><pub-id pub-id-type="pmcid">PMC7919723</pub-id><pub-id pub-id-type="pmid">33427749</pub-id></element-citation></ref><ref id="B109-viruses-13-02302"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>F.</given-names></name><etal/></person-group><article-title>SARS-CoV-2-specific immune response in COVID-19 convalescent individuals</article-title><source>Signal. Transduct. Target. Ther.</source><year>2021</year><volume>6</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1038/s41392-021-00686-1</pub-id><pub-id pub-id-type="pmid">34234102</pub-id><pub-id pub-id-type="pmcid">PMC8261819</pub-id></element-citation></ref><ref id="B110-viruses-13-02302"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moderbacher</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Ramirez</surname><given-names>S.I.</given-names></name><name name-style="western"><surname>Dan</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Grifoni</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hastie</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Weiskopf</surname><given-names>D.</given-names></name><name name-style="western"><surname>Belanger</surname><given-names>S.</given-names></name><name name-style="western"><surname>Abbott</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>C.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity</article-title><source>Cell</source><year>2020</year><volume>183</volume><fpage>996</fpage><lpage>1012</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.09.038</pub-id><pub-id pub-id-type="pmid">33010815</pub-id><pub-id pub-id-type="pmcid">PMC7494270</pub-id></element-citation></ref><ref id="B111-viruses-13-02302"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arunachalam</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Walls</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Golden</surname><given-names>N.</given-names></name><name name-style="western"><surname>Atyeo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fischinger</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Aye</surname><given-names>P.</given-names></name><name name-style="western"><surname>Navarro</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>L.</given-names></name><name name-style="western"><surname>Edara</surname><given-names>V.V.</given-names></name><etal/></person-group><article-title>Adjuvanting a subunit COVID-19 vaccine to induce protective immunity</article-title><source>Nat. Cell Biol.</source><year>2021</year><volume>594</volume><fpage>253</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03530-2</pub-id><pub-id pub-id-type="pmid">33873199</pub-id></element-citation></ref><ref id="B112-viruses-13-02302"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Richmond</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hatchuel</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Smolenov</surname><given-names>I.</given-names></name><name name-style="western"><surname>Li</surname><given-names>P.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Han</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: A phase 1, randomised, double-blind, placebo-controlled trial</article-title><source>Lancet</source><year>2021</year><volume>397</volume><fpage>682</fpage><lpage>694</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)00241-5</pub-id><pub-id pub-id-type="pmid">33524311</pub-id><pub-id pub-id-type="pmcid">PMC7906655</pub-id></element-citation></ref><ref id="B113-viruses-13-02302"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Angelopoulou</surname><given-names>A.</given-names></name><name name-style="western"><surname>Alexandris</surname><given-names>N.</given-names></name><name name-style="western"><surname>Konstantinou</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mesiakaris</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zanidis</surname><given-names>C.</given-names></name><name name-style="western"><surname>Farsalinos</surname><given-names>K.</given-names></name><name name-style="western"><surname>Poulas</surname><given-names>K.</given-names></name></person-group><article-title>Imiquimod-A toll like receptor 7 agonist-Is an ideal option for management of COVID 19</article-title><source>Environ. Res.</source><year>2020</year><volume>188</volume><fpage>109858</fpage><pub-id pub-id-type="doi">10.1016/j.envres.2020.109858</pub-id><pub-id pub-id-type="pmid">32846644</pub-id><pub-id pub-id-type="pmcid">PMC7309930</pub-id></element-citation></ref><ref id="B114-viruses-13-02302"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dyavar</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>R.</given-names></name><name name-style="western"><surname>Emani</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pawar</surname><given-names>G.P.</given-names></name><name name-style="western"><surname>Chaudhari</surname><given-names>V.D.</given-names></name><name name-style="western"><surname>Podany</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Avedissian</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Fletcher</surname><given-names>C.V.</given-names></name><name name-style="western"><surname>Salunke</surname><given-names>D.B.</given-names></name></person-group><article-title>Role of toll-like receptor 7/8 pathways in regulation of interferon response and inflammatory mediators during SARS-CoV2 infection and potential therapeutic options</article-title><source>Biomed. Pharmacother.</source><year>2021</year><volume>141</volume><fpage>111794</fpage><pub-id pub-id-type="doi">10.1016/j.biopha.2021.111794</pub-id><pub-id pub-id-type="pmid">34153851</pub-id><pub-id pub-id-type="pmcid">PMC8189763</pub-id></element-citation></ref><ref id="B115-viruses-13-02302"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khanmohammadi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rezaei</surname><given-names>N.</given-names></name></person-group><article-title>Role of Toll-like receptors in the pathogenesis of COVID-19</article-title><source>J. Med. Virol.</source><year>2021</year><volume>93</volume><fpage>2735</fpage><lpage>2739</lpage><pub-id pub-id-type="doi">10.1002/jmv.26826</pub-id><pub-id pub-id-type="pmid">33506952</pub-id><pub-id pub-id-type="pmcid">PMC8014260</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="viruses-13-02302-f001" orientation="portrait"><label>Figure 1</label><caption><p>A simplified signaling of TLR2 and TLR4 response to SARS-CoV-2 infection. Induction of inflammatory cytokines and chemokines through TLR2 and TLR4 signaling pathway in response to SARS-CoV-2 infection has been indicated.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="viruses-13-02302-g001.jpg"/></fig><table-wrap position="float" id="viruses-13-02302-t001" orientation="portrait"><object-id pub-id-type="pii">viruses-13-02302-t001_Table 1</object-id><label>Table 1</label><caption><p>TLR agonists as vaccine adjuvants for enhancing COVID-19 vaccine efficacy.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Vaccine</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sponsor</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">TLR Agonist Adjuvant</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Target TLR</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Clinical Phase of Development</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Effects on Host Immunity </th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Clinical Trials. Gov Identifier/Reference</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IMP CoVac-1<break/>(SARS-CoV-2-derived multi-peptide vaccine)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">University Hospital Tuebingen</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TLR1/2 ligand XS15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TLR1/2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Results not published yet</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04546841">NCT04546841</ext-link></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VXA-CoV2-1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vaxart</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">dsRNA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TLR3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Results not published yet</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04563702">NCT04563702</ext-link></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VXA-CoV2-1.1-S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vaxart</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">dsRNA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TLR3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Results not published yet</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05067933">NCT05067933</ext-link></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SCB-2019 vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clover Biopharmaceuticals AUS Pty Ltd.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CpG 1018 plus alum</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TLR9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Well-tolerated in healthy volunteers; elicited T-helper-1-biased CD4+ T-cell responses</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B112-viruses-13-02302" ref-type="bibr">112</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SCB-2019 vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Zhejiang Clover Biopharmaceuticals Inc.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CpG 1018 and alhydrogel</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TLR9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Results not published yet</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04954131">NCT04954131</ext-link></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SCB-2019 vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clover Biopharmaceuticals AUS Pty Ltd.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CpG 1018 plus alum</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TLR9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Results not published yet</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05012787">NCT05012787</ext-link></td></tr></tbody></table></table-wrap></floats-group></article></pmc-articleset>